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Abstract 
The initial treatment of acute lymphoblastic leukemia (ALL) leads often to the decrease of 
symptoms in patients. However, potentially remaining leukemic cells after chemotherapy, 
defined as minimal residual disease (MRD), indicate a high risk for relapse. Patients with 
relapse are faced with poor outcome. Novel treatment strategies have to target MRD cells in 
order to minimize the relapse risk. Dormancy and chemotherapy resistance are associated 
with unfavorable and critical features in MRD. However, our knowledge of MRD cells is too 
limited to allow a specific and successful treatment of these cells in patients.  
 
This present work is based on the individualized patient-derived xenograft (PDX) mouse 
model complemented with genetic engineering in PDX cells by expression of molecular 
markers and bioluminescence in vivo imaging. A novel preclinical model which uses 
prolonged chemotherapy treatment in mice to introduce MRD in PDX ALL, mimicking the 
situation in patients, was established. Histochemical studies of the murine bone marrow 
revealed that PDX MRD cells from this mouse model localized to the perivascular niche in 
the bone marrow; in contrast, in an additional, already established PDX mouse model of long-
term dormancy, dormant PDX ALL cells were preferentially enriched in the endosteal niche 
where normal hematopoietic stem cells reside. Gene expression profiles (GEP) of rare, but 
highly enriched bulk and single PDX ALL cells demonstrated high similarities between the 
PDX MRD cells and dormant PDX cells of the two different mouse models; both populations 
showed major adverse characteristics typically associated with unfavorable prognosis in 
patients such as altered metabolism and signs of chemotherapy resistance. Most importantly, 
GEP of primary ALL cells obtained from children at MRD showed a high similarity to PDX 
MRD cells indicating that the new preclinical MRD model resembles the challenging clinical 
situation of MRD in patients with ALL. 
 
The novel platform can now be used for developing innovative treatment strategies. Resistant 
ALL cells might be resolved from the bone marrow niche in order to sensitize them towards 
chemotherapy.   
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Zusammenfassung 
Die Initialtherapie der akuten lymphatischen Leukämie (ALL) führt oft zu einer Minderung 
der Symptome bei betroffenen Patienten. Jedoch bergen persistierende Leukämiezellen nach 
der Chemotherapie, definiert als minimale residuale Resterkrankung (MRD), ein erhöhtes 
Risiko für ein Rezidiv und führen folglich zu einer schlechteren Prognose. Neuartige 
Behandlungsstrategien gegen die MRD Zellen müssen entwickelt werden, um die Rezidivrate 
in ALL zu senken. Dabei werden Zellruhe und Chemotherapie-Resistenz mit kritischen 
Eigenschaften der MRD assoziiert. Jedoch ist unser Wissen über die Zellen der MRD zu 
begrenzt, um diese gezielt und erfolgreich zu bekämpfen. 
 
Diese vorliegende Arbeit basiert auf dem individualisierten Patienten-abgeleiteten Xenograft 
(PDX) Mausmodell. Ergänzt wurde dieses Modell durch Genmanipulationen an den PDX 
Zellen für die Expression von molekularen Markern und für die Biolumineszenz in vivo 
Imaging. Ein neues präklinisches Modell für die Simulation der MRD in der PDX ALL, 
welches auf eine langfristige Chemotherapie in Mäusen beruht und dabei die Situation des 
Patienten nachahmt, wurde etabliert. Histochemische Analysen von murinem Knochenmark 
ergaben, dass sich die PDX MRD Zellen aus diesem Mausmodell  in der perivaskulären 
Nische des Knochenmarks lokalisieren. Im Gegensatz dazu, in einem zusätzlichem, bereits 
etabliertem PDX Mausmodell zur langfristigen Zellruhe, waren die ruhenden PDX ALL 
Zellen in der endostalen Nische angereichert, wo sich auch die hämatopoetischen 
Stammzellen befinden. Genexpressionsprofile (GEP) von seltenen, aber hochangereicherten 
Bulk- und Einzel-PDX ALL Zellen zeigten hohe Ähnlichkeiten zwischen den PDX MRD- 
und den ruhenden PDX Zellen aus den zwei verschiedenen Mausmodellen. Beide 
Populationen wiesen wesentliche Merkmale auf, die typischerweise mit ungünstigen 
Prognosen in Patienten assoziiert sind, wie z.B. veränderter Metabolismus und Anzeichen für 
Chemotherapie-Resistenz. Vor allem zeigten die GEP von primären ALL Zellen, isoliert aus 
Kindern in der MRD, eine hohe Ähnlichkeit zu PDX MRD Zellen. Dies lässt schlussfolgern, 
dass das neue präklinische MRD Modell die klinisch herausfordernde Situation der MRD in 
ALL Patienten wiedergibt. 
 
Diese einzigartige neue Plattform eignet sich für die Entwicklung neuartiger 
Behandlungsstrategien. Resistente ALL Zellen sollten von der Knochenmarksnische zerstreut 
werden, um diese für Chemotherapie angreifbar zu machen 
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1 Introduction 
1.1 Acute Lymphoblastic Leukemia 
Acute lymphoblastic leukemia (ALL) is a malignant disorder of the lymphoblastic progenitor 
lineage. Instead of developing into mature lymphocytes, immature and non-functional blasts 
of B- or T-cells grow at high rates and accumulate in the bone marrow and infiltrate other 
organs via blood vessels. The accumulation of blasts leads to disturbed and suppressed 
hematopoiesis. Due to this dysfunction the symptoms are shown in anemia, increased risk of 
infections and bleedings, fever and the enlargement of spleen and liver (Esparza & Sakamoto. 
2005).    
ALL is the most common cancer in children and around 60% of all ALL cases occur at an age 
of 20 years and younger. Most of the affected children are between 2 and 5 years. The 
incidence is 3-4 cases per 100,000 children and 1 case per 100,000 adults each year. Among 
them B-ALL represent 80% of all ALL cases and is more frequently diagnosed in children as 
well as adults compared to T-ALL (Chiarini et al. 2016; Cobaleda & Sanchez-Garcia. 2009). 
ALL is a heterogeneous disease with genetic alterations including hyperdiploidy, 
chromosomal translocations and deletions. Chromosomal translocations are the most frequent 
alteration in ALL. In more than 20% of all pediatric cases a TEL-AML1 (synonym: ETV6-
RUNX1) translocation is detected, followed by MLL rearrangements (6%), TCF3-PBX1 (4%) 
and BCR-ABL (synonym: Philadelphia-chromosome; 2%)(Inaba et al. 2013). Many 
chromosomal rearrangements disrupt gene loci of important transcription factors regulating 
the hematopoiesis and lymphoid development (e.g. ETV6, RUNX1, TCF3, PBX1). The BCR-
ABL translocation leads to a constitutive tyrosine kinase activity resulting in uncontrolled cell 
divisions, whereas MLL rearrangements disturb the histone methylations provoking altered 
gene expressions (Ferrando et al. 2003; Raitano et al. 1995). Most of the rearrangements are 
well characterized and are used to predict treatment efficiencies. For example, high 
hyperdiploidy and ETV6-RUNX1 translocations are associated with good prognosis in 
contrast to MLL rearrangements (Inaba et al. 2013; Pui et al. 2008).  
 
1.1.1 Treatment  
The high proliferation rate of many leukemic cells is taken advantage in the ALL therapy. 
Therefore, the treatment of ALL patients is based on chemotherapy (Inaba et al. 2013). 
Cytostatic drugs target unspecific all fast dividing malignant as well as healthy cells by 
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suppressing diverse proliferating processes, e.g. inhibition of the chromosome separation 
during cell division by application of Vincristine, which is a commonly used cytostatic drug 
in ALL treatment (Owellen et al. 1972). Thus, such a therapy is correlated with severe side 
effects due to elimination and damage of dividing healthy cells. Hair loss, mouth sores, 
vomiting and increased infection risk are some of the common side effects (Clevers. 2011; 
Zhou et al. 2009). 
Most cytostatic drugs were developed before 1970 and are still very important in clinical 
treatment strategies. During the last decades the therapy protocols were optimized in dosage, 
frequency and the combination of chemotherapeutics leading to higher survival rates and 
better outcome (Inaba et al. 2013). 
The average treatment duration in ALL is 2-3 years and is divided into three phases in which 
the cytostatic drugs, dosages and frequencies are changed. After diagnosis of ALL the 
induction therapy is immediately started. The aim of the first therapy phase is reaching 
remission by reducing the initial leukemic burden and restoring normal hematopoiesis. 
Remission is reached by easing the disease symptoms. After 4-6 weeks of induction therapy, 
the success rate is more than 90%, and the following consolidation therapy aims to eliminate 
residual leukemic cells in the next 20-30 weeks. Finally, by reducing the high dosage of 
cytostatic drugs, the maintenance therapy is carried out for 2-3 years in order to decrease the 
risk of leukemia regrowth, called relapse  (Inaba et al. 2013; Pui et al. 2008). 
The survival rate depends on the ALL classification considering the detected chromosomal 
translocations. Nevertheless, not more than 50% of adults and more than 80% of children 
have a long-term survival rate of more than 5 years after diagnosis (Bassan & Hoelzer. 2011). 
The main reason for treatment failures is the occurrence of relapses. Patients with relapse 
have a dismal prognosis due to chemotherapy resistance of the re-growing leukemia. Two 
different models are described for the evolution of therapy-resistant clones causing ALL 
regrowth. Relapse arises either from an existing clone at diagnosis or from pre-leukemic 
ancestral clone, which gain a new chromosomal abnormality or gene mutation (Kunz et al. 
2015; Mullighan et al. 2008). A recent study in B-ALL compared matched diagnosis and 
relapse samples and showed that 75% of the relapse clones were already found during initial 
diagnosis (Ma et al. 2015).  
The standard ALL therapy with cytostatic drugs was optimized over the last decades and 
reached a level in which a significant increase of patients’ outcome and survival rate is not 
possible by optimizing existing chemotherapy alone. Therefore, new treatment strategies are 
urgently needed (Cooper & Brown. 2015). More and more targeted therapy for ALL becomes 
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important to support the chemotherapy. Disease specific characteristics are attacked by 
targeted therapies. The challenge in developing these personalized therapies is the 
identification of proteins that are ideally expressed in malignant but not in healthy cells or 
display at least significant different expression levels. The advantages of this new approach 
are less toxicity on healthy cells and fewer side effects than cytostatic drugs alone (Portell & 
Advani. 2014).  
The best described drug for targeted therapy in ALL is Imatinib. Imatinib binds specifically to 
the BCR-ABL1 fusion protein, which is presented exclusively in leukemic cells but not in 
healthy cells. This binding leads to the inhibition of the constitutively activated tyrosine 
kinase (Yanada et al. 2006). Thus, Imatinib has resulted in high improvement in the survival 
of BCR-ABL1 positive leukemia patients. In the last decades patients with BCR-ABL1 
translocations had a poor prognosis. Less than 40% of these patients survived after 
chemotherapy. By inhibiting the constitutively activated BCR-ABL1 kinase with Imatinib, 
combined with chemotherapy, the survival rate increased up to 80% (Schultz et al. 2009). 
In addition, many concepts of targeted therapies for ALL are in clinical studies, for example 
therapeutic antibodies as Blinatumomab and Inotuzumab ozogamicin (Portell & Advani. 
2014). Blinatumomab is the first BITE (Bi-specific T-cell engagers)-antibody, which detects 
simultaneously two different antigens, the CD3 receptor of T-cells and the CD19 cell surface 
protein of B-cells. Both proteins are overexpressed in ALL compared to healthy lymphocytes. 
Specific binding of Blinatumomab marks ALL cells for an antibody-dependent cellular 
cytotoxicity reaction of the immune system, resulting in elimination of tumor cells via 
phagocytosis by natural killer cells, monocytes or macrophages (Brower. 2016; Mellor et al. 
2013). 
In contrast, the antibody inotuzumab ozogamicin is linked to a cytostatic drug and binds to the 
cell surface marker CD22, which is highly expressed in mature B-cells and blasts. The 
progenitor B-cells are not affected. Thus, the toxicity on the B-cell lineage is low. 
Furthermore, the high side effects of conventional chemotherapy are reduced by this antibody 
due to the targeted application of the cytostatic drug in specific areas (Kantarjian et al. 2012; 
Morley & Marks. 2016).  
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1.1.2 Minimal residual disease  
Minimal residual disease (MRD) implies small numbers of remaining leukemic cells after 
reaching remission. During and after patients’ treatment the therapeutic success is followed in 
the clinics as depicted in Figure 1. Chemotherapy reduces the leukemia burden within almost 
all patients (green circle) and remission is achieved in a short period of time. Nevertheless, 
treatment has to continue after remission to avoid relapse of the disease. A level of less than 
1% of remaining ALL cells after therapy is defined as MRD (Buckley et al. 2013). Depending 
on patients’ ALL, resistant leukemic cells can persist in different levels (red circle) and cause 
sooner or later relapses. Especially, MRD levels indicate the initial response to therapy and 
serve as prognostic marker for relapse risk. Patients with the lowest detectable MRD levels 
(e.g. 10
-4
) have a better prognosis and lower risk of suffering relapse than patients with high 
levels of MRD cells (e.g. 10
-2
) (Conter et al. 2010; van Dongen et al. 2015). Even in cases of 
a complete MRD response, which is characterized by non-detectable numbers of leukemic 
cells, patients can relapse. The monitoring of the MRD level is important for assessing the 
therapeutic success and for starting treatment upon regrowth of resistant cells (Borowitz et al. 
2008; Stow et al. 2010; Vora et al. 2013).  
 
 
Figure 1: Monitoring of minimal residual disease in clinics. 
Therapeutic effects in ALL treatment are monitored in clinics. Tumor load (proportion of leukemic cells among 
healthy cells) can be reduced by chemotherapy (green circle). Remaining leukemic cells are resistant to the 
current therapy (red circle). MRD level is reached in different levels depending on patients’ ALL and serve as 
prognostic marker for relapse. Adapted from (Bruggemann et al. 2012). 
 
Identification of residual leukemic cells among healthy cells in bone marrow aspirates is 
based on leukemia specific chromosomal translocations, gene mutations, immunoglobulin 
                                                                                                                                   Introduction 
15 
 
receptor rearrangements or immunophenotypic abnormalities. Chromosomal translocations 
are highly specific for leukemia and are analyzed by polymerase chain reaction (PCR) as well 
as gene mutations and immunoglobulin receptor rearrangements (Greaves & Wiemels. 2003; 
van Dongen et al. 2015). The sensitivity can be up to 10
-6
 cells by analyzing translocations. 
The disadvantage of this method is that no information about the leukemia immunophenotype 
is gained (Bruggemann et al. 2010). This information might be useful for further therapy 
strategies. In contrast, fluorescence-activated cell sorting (FACS) analysis provides an 
immunophenotypical characterization of patients’ leukemia with the detection limit of 10
-5
 
cells (Bruggemann et al. 2010; Coustan-Smith et al. 2011). However, the challenge is to 
identify leukemia-associated immunophenotypes that are different from present normal bone 
marrow cells. Until now no common MRD signature exists due to the high variation of ALL 
(Basso et al. 2009; Coustan-Smith et al. 2011). Therefore, the leukemic antigen expression 
pattern of every patient has to be adjusted by using a leukemia-associated panel of at least 6 
relevant markers, for example CD19, CD22, CD34, CD38, CD45 are the most common 
markers for identification of ALL cells in the bone marrow (Borowitz et al. 2008; Fiser et al. 
2012). Nevertheless, false positivity still cannot be completely excluded because of 
similarities between leukemic lymphoblasts and normal lymphoid progenitor cells in the 
different phases of regeneration during and after treatment. (Basso et al. 2009; Coustan-Smith 
et al. 2011).  
The challenge in the ALL therapy is not anymore the initial treatment to reach remission. The 
survival rate is more than 90% after the induction therapy (see 1.1.1). Remaining treatment- 
resistant MRD cells after chemotherapy are the main reason for regrowth of the leukemia. 
More ALL patients succumb of relapses than from the initial cancer. A better understanding 
of MRD cells would provide new insights for developing targeted therapies against MRD 
cells (Campana. 2010; Vora et al. 2013). 
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1.1.3 The role of the bone marrow 
It is currently believed that the bone marrow environment plays a pivotal role in dormancy 
and chemotherapy resistance of leukemic cells (Pal et al. 2016). Colmone and colleagues 
presented the first important evidence for the interaction between bone marrow and leukemic 
cells. They demonstrated that leukemic cells are able to change the bone marrow 
microenvironment resulting in a dysfunction of hematopoietic progenitor cells (HPC) 
(Colmone et al. 2008). 
Increasing understanding of the bone marrow structure and healthy hematopoiesis led to new 
insights of the leukemic niche. A niche is defined as a local microenvironment maintaining 
and regulating stem cells and progenitors (Morrison & Scadden. 2014). Two niches exist in 
the bone marrow: the endosteal- and perivascular niche (Chiarini et al. 2016; Ehninger & 
Trumpp. 2011; Lo Celso & Scadden. 2011). The endosteal niche (endosteum) is the region 
around the bone matrix with a distance of less than 100 µm to the closest bone matrix 
(Nombela-Arrieta et al. 2013). The perivascular niche is more central within the bone marrow 
consisting of sinusoids/endothelial cells, CXCL12-abundant reticular (CAR) cells and 
mesenchymal stem cells (MSC). These cell types are also found in the endosteal region, but 
with a lower frequency (Ehninger & Trumpp. 2011). Characteristic cells for the endosteal 
niche are osteoblasts and osteoclasts, which build a cell layer on the bone matrix. The 
function of all cell types are more or less known: Osteoblasts synthesize and osteoclasts 
resorb the bone matrix during bone formation, and CAR cells produce excessively the 
chemokine CXCL12 for homing and maintaining HSC in the bone marrow (Chiarini et al. 
2016; Sugiyama et al. 2006). However, the knowledge about the interaction of these cell types 
within the microenvironment by secreted cytokines and cell surface ligands/receptors is still 
incomplete (Morrison & Scadden. 2014). Furthermore, a controversial issue exists about the 
localization of dormant HSC within the bone marrow. Many groups indicated that the 
endosteal niche maintains a small dormant HSC population in contrast to the perivascular 
niche harboring self-renewing HSC (Arai & Suda. 2007; Calvi et al. 2003; Haylock et al. 
2007; Zhang et al. 2003). However, recent studies from laboratory of Prof. Morrison (UT 
Sothwestern Medical Center, Dallas) showed that the function of the endosteal niche is 
minimized to an indirect role in modulating HSC. The perivascular niche is settled by HSC 
and the endosteal niche by early lymphoid progenitors (Ding & Morrison. 2013). 
Furthermore, it was stated that dividing HSC are localized more likely in the endosteum than 
non-dividing HSC, which are restricted to perivascular subniches (Acar et al. 2015; Morrison 
& Scadden. 2014).   
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Figure 2: Bone marrow is divided into two major niches. 
The bone marrow consists of the endosteal- and the perivascular niche for maintaining self-renewal and lineage 
differentiation of hematopoietic stem cells (HSC). The endosteal niche is close to the bone matrix and the 
perivascular niche is located more in the center of the bone marrow and is not influenced by osteoblasts and 
osteoclasts. The endosteal niche plays an important role for HSC dormancy, and the perivascular niche harbors 
dividing HSC. However this is controversially discussed. Adapted from (Ehninger & Trumpp. 2011). 
 
In contrast to the controversially discussed role of the endosteal niche in the HSC 
maintenance, the role of the endosteum is clearer in the malignant hematopoiesis. Several 
studies demonstrated that the endosteal niche is associated with dormant and chemotherapy-
resistant leukemic cells (Boyerinas et al. 2013; Chen et al. 2014; Ishikawa et al. 2007). Within 
the endosteal region leukemic cells interact with the cellular environment. Often some 
features of osteoblasts and osteoclasts are used or disturbed to gain an advantage in leukemia 
progression (Kode et al. 2014; Lawson et al. 2015; Schepers et al.). For example, Boyerinas 
and colleagues showed that blasts use osteopontin to localize themselves in the quiescent 
endosteal niche. Osteopontin, which is secreted by osteoblasts, acts as a chemokine and as an 
extracellular protein for bone remodeling. After homing in this niche, the leukemic cells start 
to produce and to secrete additional osteopontin into the local microenvironment in order to 
enhance the dormant effect (Boyerinas et al. 2013). 
Next to the leukemia supporting endosteal niche, malignant cells are also able to evolve a 
protective niche by interacting with MSC during chemotherapeutical stress. The formation of 
a therapy-induced niche contributes to the chemotherapeutic resistance of leukemic cells 
(Duan et al. 2014).  
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Recently, new insights were obtained in understanding the interaction of leukemia with the 
microenvironment. The bone marrow supports the dormancy and chemotherapy resistance of 
leukemic cells (Pal et al. 2016). Novel ALL treatment strategies have to consider the bone 
marrow environment. By targeting the interaction of leukemia and bone marrow, drug 
resistant leukemic cells can be sensitized towards chemotherapy.  
 
 
1.2 Challenging characteristics of tumor cells 
In patients’ remission, infinitesimal numbers of MRD cells can remain after conventional 
chemotherapy and indicate a risk for the reappearance of leukemia followed with bad 
prognosis. The final goal of all cancer therapies is to cure the patient by reaching a complete 
recovery without any risk of relapse. In clinics conventional chemotherapies usually do not 
overcome the challenging characteristics of relapse inducing cells. Unfavorable and 
challenging characteristics of these tumor cells are associated with quiescence, drug resistance 
and stemness (Kreso & Dick. 2014).    
  
1.2.1 Dormancy 
Therapeutic success is diminished by the existence of dormant cancer cells. Elimination of 
this inactive and non-dividing subpopulation is limited by the mode of action of conventional 
drugs. Most drugs in cancer therapy are cytostatic agents targeting different cellular processes 
for proliferation. Consequently, dividing cancer cells are killed, and dormant cells remain as 
the drugs are not affecting non-dividing dormant cells. These cells represent the residual 
disease and might be dormant over a long time period until starting to proliferate and resulting 
in relapse. Mechanisms of dormancy are still unclear in cancer cells (Essers & Trumpp. 2010; 
Greaves. 2013; Li et al. 2014). However, the microenvironment is very likely to have a crucial 
role at this critical feature. Novel treatment strategies aim to target dormant cancer cells or 
alter the microenvironment in order to re-activate the cell cycle and sensitize them towards 
chemotherapy (Saito et al. 2010). 
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1.2.2 Drug resistance 
Chemotherapy resistance is another challenging and critical feature influencing patients’ 
outcome. During drug treatment, some cancer cells escape from therapy and lead to a more 
aggressive and resistant disease. Here two different scenarios are conceivable to explain the 
drug resistance: either chemotherapy induces genetic alterations in cancer cells leading to a 
resistance or a chemotherapy-resistant subclone already existed within the initial tumor 
population. The molecular reasons for drug resistance are manifold and poorly understood so 
far. However, proteasome inhibition, altered membrane transport, altered target enzyme, 
decreased drug activation and increased drug degradation are one of many suggestions for 
causing intrinsic drug resistance (Luqmani. 2005; Paiva et al. 2016). 
Extrinsic regulators were also implicated for drug resistance. The tumor microenvironment 
contributes to keep cancer cells in a dormant state (Boyerinas et al. 2013; Chen et al. 2014). 
This acquired dormancy leads to chemotherapy resistance due to downregulation of cell cycle 
processes (Li et al. 2014). Besides, the surrounding microenvironment might also inhibit the 
drug distribution resulting in protection of cancer cells (Meads et al. 2009). 
In summary, new drugs with novel mode of actions are urgently needed to overcome 
resistances during chemotherapy. 
 
1.2.3 Stemness 
Therapy failures are also caused by the heterogeneity of the tumor. A tumor population 
consists of multi-clonal divergent fast-dividing and drug-sensitive cells. The cancer stem cell 
(CSC) model proposes that a tumor arises from a rare subgroup of dormant and drug resistant 
cells with self-renewal capacity. CSC constitute the malignant counterpart to stem cells, 
which are distinguished from CSC by the balance between proliferation and quiescence 
affected by the specific niche (Li & Neaves. 2006). Self-renewal of CSC is crucial for the 
maintenance and also for the relapse of the tumor. Asymmetric division of one CSC gives rise 
to two distinct daughter cells: one copy of the original stem cell and a second cell to 
differentiate into a non-stem tumor cell (Greaves. 2013; Magee et al. 2012; Shackleton. 2010). 
Furthermore, in one tumor several CSC clones might exist with diverse genotypes and 
phenotypes. By targeting and eliminating CSC, the source of tumor growth might be inhibited 
and the disease might become favorable and sensitive for treatments. Therefore, such 
treatment strategies try to target malignant cells with CSC characteristics (Clevers. 2011; 
Kreso & Dick. 2014). 
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The standard assay for identification and quantification of CSC in tumors is based on the 
xenograft tumor model. Cancer cells are transplanted into mice in dilution series allowing the 
calculation of CSC frequency from the number of engrafted cells. In general, CSC frequency 
is considered far below 0.1% of an unsorted cancer cell population (Iwasaki & Suda. 2009; 
Lapidot et al. 1994). However, the used CSC markers in all different types of tumors show 
controversial results. Consequently, these markers cannot be used for a precise detection of 
CSC in tumors  (Clevers. 2011).  
 
An exception of the hierarchical CSC model in tumors is ALL. An enormous cellular 
heterogeneity and clonal evolution is observed in ALL. Besides, all ALL cells have the 
capacity for self-renewal and therefore are attributed with CSC potential, termed as leukemia 
stem cells (LSC). The LSC frequency in ALL is very high compared to other types of cancer 
and leukemia. A stochastic model is even suggested to describe the LSC of ALL (Morisot et 
al. 2010; Vormoor. 2009).  Consequently, no specific LSC markers have been defined so far 
for ALL (Kong et al. 2008).  
 
Taken together, all challenging characteristics of dormancy, drug resistance and stemness 
have to be considered for developing new treatment strategies in order to improve patients’ 
outcome especially after relapses. 
 
1.3 Patient-derived xenograft mouse model of ALL 
The patient-derived xenograft (PDX) ALL mouse model is based on primary patients’ cells 
and is currently the best model for studying many diverse aspects of human leukemia (Poglio 
et al. 2016).  
The PDX model was first described by John Dick and colleagues around 30 years ago 
(Kamel-Reid et al. 1989) and its importance increases continuously each year. This model is 
currently the gold standard model for analyzing the leukemia niche (Duan et al. 2014; 
Hawkins et al. 2016; Ninomiya et al. 2007), studying the clonal evolution of leukemic cells 
(Cheung et al. 2013; Clappier et al. 2011), performing preclinical treatment trials (Gao et al. 
2015; Lee et al. 2007; Townsend et al. 2016) and advancing translational leukemia research 
(Fry & Aplan. 2015; Guezguez et al. 2013; Hidalgo et al. 2014). 
For PDX-based studies in ALL, primary material is obtained from patients’ bone marrow 
aspirates or peripheral blood. By injecting the primary ALL cells into immunocompromised 
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mice, human leukemia engrafts in the living organism and displays similar course of disease 
as in patients. Leukemic cells home and engraft first in the bone marrow before they expand 
and infiltrate other organs like spleen and liver. Leukemic PDX cells can be re-isolated from 
the bone marrow or spleen, and re-injected into the recipient mice for passaging 
(Gopalakrishnapillai et al. 2016).  
An in vivo model is required for primary ALL cells as they are unfortunately reluctant to grow 
in vitro. Amplification of primary ALL cells requires passaging in vivo. In rare occasions, in 
vitro growing cell lines can be generated out of primary ALL cells. These cell lines acquire 
additional mutations and alterations which are not present in patients and introduce a major 
bias into all studies. In contrast, upon in vivo passaging PDX cells retain important 
characteristics of primary ALL cells, for example microenvironment interactions or molecular 
heterogeneity (Cassidy et al. 2015; Townsend et al. 2016). 
The similarity between primary ALL and the PDX model was shown by comparing primary 
samples of diagnosis and relapse with their behavior as PDX. More aggressive types of 
leukemia and especially relapse samples engraft more efficient and faster in recipient mice 
than diagnosis samples. (Lock et al. 2002; Meyer et al. 2011). Furthermore, Clappier and 
colleagues demonstrated that the PDX cell population often arises from minor subclones 
existing in patients’ diagnosis. These subclones are found predominantly in the corresponding 
relapse samples.  Engrafted ALL cells resemble in the xenograft mouse model more 
aggressive relapse samples than diagnosis samples (Clappier et al. 2011). 
Engrafted ALL samples have a high stemness frequency in the xenograft mouse model. Small 
numbers of ALL cells are injected into mice without enriching for any self-renewal marker 
like in other xenograft models. Thus, the efficiency of establishing new PDX ALL samples is 
very high compared to other cancer types or leukemia models (Morisot et al. 2010).  
 
1.3.1 PDX mouse model for identification of dormant leukemic cells 
The PDX mouse model of ALL was developed further in our lab by introducing lentiviral 
transduction for molecular manipulation in PDX cells (Terziyska et al. 2012; Vick et al. 
2015). After a first passage of the primary sample in an immunocompromised mouse, 
lentiviral transduction is performed ex vivo to obtain PDX cells positive for reporter genes 
facilitating enrichment and detection of PDX cells (see Figure 3) (Terziyska et al. 2012; Vick 
et al. 2015). 
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Figure 3: Scheme for production of transgenic PDX ALL cells. 
Primary ALL samples from the clinics can be passaged in the immunocompromised NOD scid gamma (NSG) 
mice. After the first passage lentiviral transduction is performed to the isolated PDX cells from the enlarged 
spleens. PDX cells were transduced with the following transgenes: truncated NGFR for magnetic-activated cell 
sorting (MACS) targeting, mCherry for FACS detection and luciferase for bioluminescence in vivo imaging. 
Enriched transgenic PDX cells are reinjected. Adapted from (Ebinger, Özdemir et al. 2016). 
 
In a parallel independent but collaborative PhD activity, Sarah Ebinger studied dormant ALL 
PDX cells. The identification and isolation of the dormant PDX cells were facilitated by the 
expressed transgenes luciferase, a red fluorochrome and the artificial surface antigen NGFR. 
(Ebinger, Özdemir et al. 2016). While transgenic luciferase was used for in vivo imaging and 
follow-up of the disease, the other two transgenes were used to isolate and enrich minor 
amounts of PDX ALL cells from murine bone marrow by a two-step procedure consisting of 
a magnetic-activated cell sorting (MACS) enrichment step using NGFR followed by a FACS 
enrichment using the fluorochrome. PDX cells were additionally labeled with the fluorescent 
cell staining dye, CFSE (Carboxyfluorescein succinimidyl ester) ex vivo (Weston & Parish. 
1990). CFSE is an accepted marker for dormant cells. Each cell division diminishes the CFSE 
signal by 50%. Loss of the CFSE intensity is associated with continuous proliferation. 
Triple transgenic, CFSE
+
 PDX cells were injected into immunocompromised mice. After 
several weeks of cell injection the bone marrow was isolated and analyzed for the PDX cells. 
A small subpopulation of CFSE
+
 PDX cells was identified after 3 weeks of injection. These 
cells did not lose the staining dye and are called label retaining cells (LRC; see Figure 4). 
Two weeks after cell injection the identified LRC population constitute less than 0.1% of the 
PDX population in almost all analyzed ALL samples. These samples harbor various genetic 
alterations. While almost all PDX cells proliferate in mice and loose consequently the CFSE 
signal, the LRC show a dormant phenotype and retain the CFSE. 
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Figure 4: Scheme of the PDX LRC mouse model for identification of dormant leukemic cells in vivo. 
Freshly isolated transgenic PDX cells from the spleen of the donor mice are labeled ex vivo with the proliferation 
marker CFSE. CFSE
+
 PDX cells are injected into recipient mice. After several days the bone marrow is isolated. 
Resting PDX cells, which are characterized by their high CFSE signal, are called label retaining cells (LRC). 
The more days after injection the mice are sacrificed, the less LRC are isolated. The first time point, in which 
LRC are identified, is at day 10 after cell injection. LRC are defined as less than 2% of the entire PDX 
population and are isolated from the bone marrow and enriched by MACS and FACS via their transgenic PDX 
markers of NGFR, mCherry and the CFSE signal. Adapted from (Ebinger, Özdemir et al. 2016).  
 
In functional studies, performed by Sarah Ebinger, LRC showed the critical cancer stem cells 
properties of dormancy, drug resistance and stemness. Before re-injecting the sorted LRC and 
the dividing PDX cells (non-LRC) into recipient mice, non-LRC were labeled again with 
CFSE as the marker was lost during the first passage. The same previous observed CFSE 
pattern was reproduced for both groups. Non-LRC converted into LRC and vice versa upon 
re-transplantation. Furthermore, in a limiting dilution transplantation assay (Schluter & Kaur. 
2013) LRC were not enriched for stemness compared to the dividing non-LRC. Both 
populations were able to re-engraft with the same frequency and show a high plasticity in 
mice (Ebinger, Özdemir et al. 2016).  
In in vivo treatment experiments LRC were drug resistant. In contrast, non-LRC showed a 
high sensitivity towards chemotherapy and was dramatically reduced. Sorted chemotherapy 
treated LRC inherited still leukemia-initiating potential in recipient mice, which resembled 
patients’ relapse after treatment. By taking the LRC and non-LRC out of the bone marrow 
environment and treating them with chemotherapy in vitro, both groups exhibited same drug 
sensitivities suggesting the important connection between chemotherapy resistance, ALL 
plasticity and bone marrow environment (Ebinger, Özdemir et al. 2016).  
In summary, functional studies showed that LRC obtain all critical features of challenging 
cells in patients’ treatment. The LRC fate of dormancy, chemotherapy resistance and 
stemness are highly associated with the influence of the bone marrow environment. 
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This previously established PDX LRC mouse model was used in the following thesis for 
further characterization of LRC. 
   
1.4 Aim of this work 
Conventional therapy of ALL is based on the excessive application of chemotherapeutic 
drugs. The initial treatment is often successful and patients reach remission. However, certain 
ALL cells might survive in a disease status called minimal residual disease. MRD cells might 
progress into disease relapse with poor prognosis. Novel treatment options are required to 
eliminate tumor cells at MRD in order to prevent disease relapse; but developing such 
treatments requires appropriate preclinical models which were so far lacking.  
The aim of the present study was to characterize ALL cells at MRD in order to lay the ground 
for developing novel therapies against these clinically challenging cells. As a first step, a 
preclinical PDX ALL model of MRD should be established in order to obtain reliable and 
numerous material for research. As a second step, the localization of PDX MRD cells in the 
murine bone marrow should be determined in direct comparison to dormant PDX ALL cells. 
In a third and last step, gene expression profiles should be obtained from PDX MRD cells and 
dormant PDX cells, and be compared to profiles from primary ALL cells from patients at 
MRD. Taken together, the present work aimed at a better understanding of MRD in ALL in 
order to enable developing novel therapies in the future. 
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2 Materials 
2.1 Primary material 
For gene expression profiles of patients’ pediatric B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL), thawed aspirates at the stage of diagnosis and minimal residual disease 
(MRD) were provided and sorted in TCL buffer (see 3.2.9) by the cooperation partner from 
Children's Cancer Research Institute and St. Anna Kinderspital (Department of Pediatrics, 
Medical University of Vienna, Austria) (see Table 1).  
Table 1: Sorted primary ALL samples at the stage of diagnosis and MRD   
sample 
type of 
leukemia 
age
 
[years] 
sex 
multi-center 
study 
BM blasts  at 
MRD* [%] 
Sort 
1 BCP-ALL 4 F BFM 2009 na 
CD19
+
, CD10
+
, 
CD20
-
 
2 BCP-ALL 3 F BFM 2009 na 
CD19
+
, CD99
+
, 
CD10
+
 
3 BCP-ALL 5 M BFM 2009 0.69 
CD19
+
, CD10
+
, 
CD123
+
 
4 BCP-ALL 18 M BFM 2009 1.10 
CD19
+
, CD10
+
, 
CD45
-
 
5 BCP-ALL 3 F BFM 2009 0.13 
CD19
+
, 
CD10
+
,CD20
-
 
F = female; M = male; BFM = Berlin-Frankfurt-Münster; BM = bone marrow; na = not applicable;          
* MRD aspirates were taken at day 33 after onset of treatment; 
 
2.2 Transgenic PDX cells 
In this thesis two pediatric BCP-ALL samples, which were kindly provided from Dr. von 
Haunersches Kinderspital (LMU, Munich, Germany), were used consistently in the patient-
derived xenograft (PDX) mouse models (see Table 2).  
Table 2: Clinical data of patients’ diagnostic ALL cells for xenotransplantation and sample characteristics 
sample 
type of 
leukemia 
disease 
stage 
age
 
[years] 
sex cytogenetics 
passaging 
time
§
 
[days] 
ALL-199 BCP-ALL 2
nd
 relapse 8 F 
somatic trisomy 21; 
leukemic homozygous 
9p deletion 
35 
ALL-265 BCP-ALL 1
st
 relapse 5 F 
hyperdiploidy with 
additional 6, 13, 14, 17, 
18, 21, X chromosome 
40 
§ 
passaging time in mice injected with at least 1 million cells until end stage of leukemia;  
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After transduction with the third-generation lentivirus vector system (Dull et al. 1998) by our 
institute members, both PDX samples, ALL-199 and ALL-265, expressed the following 
transgenes and were enriched to a 100% transgenic population (see Figure 5) (Ebinger, 
Özdemir et al. 2016): firefly luciferase for in vivo imaging (see 3.2.5), mCherry as a PDX 
marker and truncated NGFR without any intracellular part for magnetic-activated cell sorting 
(MACS) enrichment (see 3.2.8).  
 
Figure 5: Lentiviral construct for equimolar expression of 3 transgenes in PDX cells.  
Arrow indicates transcription start site; EF1α = elongation factor 1-alpha promoter; mCherry = red fluorescent 
protein from Discosoma sp.; NGFR = human low affinity nerve growth factor receptor lacking the intracellular 
signaling domain; T2A = self-cleaving peptide from Thosea asigna virus for linking the genes (Kim et al. 2011). 
  
2.3 Antibodies 
Table 3: Antibodies 
name host application supplier 
anti-human-CD38-PE mouse FACS BD Biosciences, Germany 
anti-murine-CD45-APC (30-F11) rat FACS Biolegend, USA 
anti-human NGFR beads - MACS Miltenyi, Germany 
anti-FITC rabbit IHC Thermo Fisher Scientific, USA 
anti-mCherry rabbit IHC Abcam, UK 
anti-rabbit-Alexa594 goat sec. ab Invitrogen, USA 
FACS = fluorescence-activated cell sorting; IHC = immunohistochemistry; sec. ab = secondary antibody; 
 
2.4 Fluorophores 
The lasers, filters and detectors of the BD FACS machines and the Leica TCS SP5 II confocal 
microscope (see 2.7) were adjusted to the following fluorophores with their specific 
spectrums.  
                               Table 4: Fluorophores with maximum excitation and emission 
name excitation [nm] emission[nm] 
DAPI 358 461 
CFSE 492 517 
PE 496 578 
mCherry 587 610 
Alexa 594 590 617 
APC 652 658 
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2.5 Buffer and medium 
Table 5: Buffer and medium 
name composition 
blocking buffer PBS with 5% goat serum & 0.1% Tween-20  
patient medium 
RPMI-1640 supplemented with 20% FCS, 1% pen/strep,  
1% gentamycin and 2 mM glutamine 
PBS 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, pH 7.2 
PBE PBS with 0.5% BSA & 5 mM EDTA 
TCL-buffer 1x TCL buffer diluted with dd H20 with 1% β-Mercaptoethanol 
 
2.6 Chemicals, reagents & kits 
                  Table 6: Chemicals, reagents & kits 
name supplier 
Baytril 2.5% Bayer, Germany 
bovine serum albumin (BSA) Sigma-Aldrich, Germany 
CellTrace CFSE Kit Life Technologies, USA 
Cyclophosphamide TEVA GmbH, Germany 
DAPI Sigma-Aldrich, Germany 
D-Luciferin, sodium salt *UltraPure Biomol, Germany 
DMSO Sigma-Aldrich, Germany 
DNase Sigma-Aldrich, Germany 
EDTA Sigma-Aldrich, Germany 
ethanol ≥99,8%, p.a Carl Roth, Germany 
FACS Lysing solution BD Biosciences, Germany 
fetal bovine serum (FCS) PAN Biotech, UK 
Ficoll GE Healthcare, UK 
gentamycin Lonza, Switzerland 
glutamine Gibco, USA 
goat serum Gibco, USA 
heparin Ratiopharm, Germany 
isoflurane CP pharma, Germany 
isopropyl alcohol Sigma-Aldrich, Germany 
KCl Sigma-Aldrich, Germany 
Na2HPO4 Merck Millipore; Germany 
NaCl Sigma-Aldrich, Germany 
O.C.T. compound Sakura, USA 
Osteosoft Merck Millipore; Germany 
penicillin-streptomycin 5000 U / ml Gibco, USA 
prolong gold antifade mounting Life Technologies, USA 
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RPMI-1640 Gibco, USA 
sucrose Sigma-Aldrich, Germany 
TCL buffer (2x) Qiagen, Germany 
trypan blue Sigma-Aldrich, Germany 
Tween-20 Sigma-Aldrich, Germany 
Vincristine cell pharm GmbH, Germany 
zinc formalin Sigma-Aldrich, Germany 
β-Mercaptoethanol Calbiochem 
 
2.7 Equipment 
                 Table 7: Equipment 
Equipment Manufacturer 
Axiovert 200M microscope Zeiss, Germany 
Calibration Check pH-Meter HI 221 HANNA Instrument,Germany 
BD FACSCalibur BD Biosciences, Germany 
BD LSRAriaIII  BD Biosciences, Germany 
BD LSRFortessa  BD Biosciences, Germany 
CryoJane tape transfer system Leica, Germany 
Cryostat CM1900UV Leica, Germany 
Fluidgm C1 Fluigm, USA 
Heracell™ 150i CO2 Incubator ThermoFisher Scientific, USA 
IVIS Lumina II Imaging System PerkinElmer, USA 
Laminar Flow Hood Heraeus, Germany 
Leica TCS SP5 II confocal microscope Leica, Germany 
Microcentrifuge 5417C Eppendorf, Germany 
Rotanta 460R centrifuge Hettich, Germany 
 
2.8 Software 
Endnote X7 
FlowJo V10 
Gimp 2 
GraphPad Prism 6 
ImageJ 
javaGSEA Desktop application 
Living Image software 4.4 
Microsoft Office 
R Studio 
                                                                                                                                        Methods 
29 
 
3 Methods 
3.1 Ethical issues 
3.1.1 Patient material 
Written informed consent was obtained from all patients’ parents/carers. For clinical routine 
analysis at the Dr. von Haunersches Kinderspital (LMU, Munich, Germany) and St. Anna 
Kinderspital (Medical University of Vienna, Vienna, Austria) fresh patient material was 
obtained from peripheral blood or bone marrow aspirates before treatment start. The 
remaining material was sent to our institute.  
The study was performed in accordance with the ethical standards of the responsible 
committee on human experimentation (written approval by Ethikkommission des Klinikums 
der Ludwig-Maximilians-Universität München, Ethikkommission@med.unimuenchen.de, 
April 2008, number 068-08, and September 2010, number 222-10) and with the Helsinki 
Declaration of 1975, as revised in 2000.  
 
3.1.2 Animal work 
The maintenance of the NOD scid gamma (NSG; NOD.Cg-Prkdc
scid
 IL2rg
tm1Wjl
/SzJ) mice 
from the Jackson Laboratory (Sweden) was done under specific pathogen-free conditions in 
the research animal facility of the Helmholtz Zentrum München. Free access to food and 
water, a 12 hour light-dark cycle and constant temperature were provided for the animals.  
All animal trials were performed in accordance with the current ethical standards of the 
official committee on animal experimentation (written approval by Regierung von 
Oberbayern, poststelle@reg-ob.bayern.de, July 2010, number 55.2-1-54-2531-95-10; July 
2010, number 55.2-1-54-2531.6-10-10; January 2016, number 55.2-1-54-2532-193-2015; 
May 2010, number 55.2-1-54-2532-193-2015 and August 2016, number 55.2-1-54-2532.0-
56-2016). Animals were sacrificed before first clinical signs of illness became apparent. 
 
 
                                                                                                                                        Methods 
30 
 
3.2 Xenograft mouse model of acute lymphoblastic leukemia 
The established acute lymphoblastic leukemia (ALL) xenograft mouse model in our institute 
is based on the immunocompromised NSG mice (Kamel-Reid et al. 1989; Lee et al. 2007; 
Liem et al. 2004; Terziyska et al. 2012).  
 
3.2.1 PDX cell engraftment and expansion 
For reliable engraftment and a shorter passaging time of the samples, 1-10 million fresh or 
freshly thawed ALL patient-derived xenograft (PDX) cells (in 100 µl sterile filtered PBS) 
were injected into 6-8 weeks old NSG mice via tail vein injection. Directly after cell injection, 
Baytril (2.5%, Bayer, Germany) was added to the drinking water of the mice in order to 
prevent infections. 
Every two weeks a blood measurement was performed to detect the expansion of human PDX 
cells in peripheral blood (see 3.2.2). At a certain percentage of PDX cells in blood, which 
correlates with engrafting leukemia, mice were sacrificed and the PDX cells were isolated 
from the enlarged spleen (see 3.2.3) or the bone marrow (see 3.2.4). Definition of high PDX 
percentage in blood was depending on the sample. Mice with ALL-199 had to be sacrificed 
with around 30% of blasts in the blood, in contrast to the sample ALL-265, in which the limit 
was 80%. Re-passaging was always possible in both PDX samples (see 2.2). In addition to the 
blood measurement, in vivo imaging was performed to analyze the leukemia burden in mice. 
The advantage of this method was the high accuracy (see 3.2.5). For the verification of the 
samples, repetitive finger printing analysis, using mitochondrial DNA, was performed 
continuously in our institute (Hutter et al. 2004). 
 
3.2.2 Blood measurement for monitoring the leukemia growth 
Every second week leukemia growth was monitored by blood measurement for each PDX cell 
injected mouse. Blood (around 50 µl) from the tail vein was collected with a heparin coated 
glass capillary into a reaction tube with 5 µl heparin. The blood samples were incubated with 
0.5 µl anti-human CD38 conjugated with phycoerythrin (PE) and 0.5 µl anti-mouse CD45 
conjugated with allophycocyanin (APC) for 30 min at room temperature (RT). Subsequently, 
1 ml FACS Lysing solution was added and incubated for 15 min at RT. Blood samples were 
washed twice with 3 ml FACS buffer. Each washing step included centrifugation at 300 g for 
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5 min at RT. Afterwards flow cytometric analysis was performed with a BD FACSCalibur 
(BD Biosciences, Germany) and the data were analyzed using the FlowJo software.  
 
3.2.3 Isolation of PDX cells from spleen 
High advanced leukemia in mice correlates with an enlarged spleen due to enrichment of ALL 
cells. After isolating the spleen, the organ was homogenized and a cell suspension in 30 ml 
PBS was prepared using a 70 µm strainer. Afterwards, 10 ml Ficoll was added to the cell 
suspension with a long needle and centrifuged with 400 g for 30 min at RT without rotor 
brake. The layer with mononuclear cells in the interphase of the Ficoll gradient centrifugation 
was harvested. Cells were washed twice with PBS (400 g, 5 min, RT) and resuspended in the 
required buffer. 
 
3.2.4 Isolation of PDX cells from bone marrow 
For isolation of PDX cells from bone marrow both femurs, both tibias, hip, backbone and 
sternum of each mouse were crushed by using mortar and pestle. The bone marrow was 
suspended with PBS and a cell suspension was prepared using a 70 µm cell strainer. After 
washing (2x, 400 g, 5 min, RT) the pellets were resuspended in the required buffer  
 
3.2.5 Bioluminescence in vivo imaging for monitoring the leukemia burden 
The transgenic PDX cells (see 2.2) expressed the recombinant codon-optimized form of the 
firefly luciferase (effluc). Therefore, it was possible to monitor the leukemia burden with 
bioluminescence in vivo imaging (Barrett et al. 2011; Bomken et al. 2013; Terziyska et al. 
2012). 
D-Luciferin, the substrate of the firefly luciferase to generate bioluminescence, was dissolved 
in sterile PBS to a final concentration of 30 mg/ml.  After anesthetizing with isoflurane the 
mice were fastened in the imaging chamber of the IVIS Lumina II Imaging System 
(PerkinElmer, USA), and 150 mg/kg D-Luciferin was injected into the tail vein. The 
generated bioluminescence was measured immediately and pictures were taken for several 
seconds up to minutes, depending to leukemia burden. The following settings were used: 
field of view = 12.5 cm; binning = 8, f/stop 1 and open filter.   
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The bioluminescence quantification was done with the software Living Image software 4.4 to 
get the leukemia burden in the unit lg photons s
-1
 (photons per second per cm
2
 per steradian). 
 
3.2.6 Quantification of PDX cell percentage in the bone marrow 
Treatment start, stop and efficiency were determined by quantification of the relative amount 
of PDX cells in the bone marrow. The entire bone marrow was isolated, crushed and collected 
in 10 ml PBS (see 3.2.4). 1/20 of the bone marrow suspension was measured by the FACS 
Fortessa (BD Biosciences, USA) and finally analyzed using the software FlowJo. The number 
of mCherry-positive (mCherry
+
) PDX cells was related to absolute event number without 
debris. The gating strategy is exemplary shown in Figure 6.  
 
      
Figure 6: Gating strategy for determination of the relative PDX cell amount in the murine bone marrow. 
The first gating (left panel) included all events in the forward- and side scatter (FSC &SSC) apart from the 
debris, in the lower left part. Afterwards, the lymphocyte gate (middle panel) was set in the FSC and SSC. 
Finally, the mCherry
+
 and DAPI
-
 PDX population were gated. DAPI was added to the sample before FACS 
analysis. A negative DAPI signal correlates with a functional cell membrane and so for living cells.  
 
3.2.7 In vivo treatment 
In this study the commonly used cytostatic drugs of patients’ ALL therapy, Vincristine (VCR; 
0.25/0.5 mg/kg; i.v.) and Cyclophosphamide (Cyclo; 100 mg/kg; i.p.), were used to generate a 
drug treated/resistant PDX cell population in mice. After reaching high leukemia burden both 
PDX ALL samples (see 2.2) received the same drug concentrations once weekly for several 
weeks. Therapy start and efficiency was determined by bioluminescence in vivo imaging (see 
3.2.5) and analysis of the PDX cell percentage in the bone marrow (see 3.2.4). In combination 
therapy VCR was injected two days before Cyclo because of the longer half-life of VCR (85 
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h) compared to Cyclo (7 h). Control animals received sterile PBS i.p. or i.v.. Drug solutions 
were prepared freshly with sterile PBS. 
Human equivalent doses were calculated for mouse treatments to be close to the clinics (see 
Table 8). Following calculations were used (Nair & Jacob. 2016; Sharma & McNeill. 2009): 
 
                                                       
  
  
  
              
  
  
  
 
 
               
  
  
               
  
  
        
 
The conversion between human dose in mg/kg and mg/m² is done by the defined factor of 37. 
On the basis of the faster metabolism in mice, the human dose in mg/kg has to be multiplied 
with the factor of 12.3 to get the equivalent murine dose.   
                                 Table 8: Used drug concentrations in mice and patients 
drug 
mg/m² 
patient 
mg/kg 
patient 
mg/kg  
mouse 
(theory) 
mg/kg 
mouse 
(used) 
Vincristine 1.4 0.04 0.47 0.5 
Cyclo-
phosphamide 
200 5.4 66.5 100 
 
3.2.8 Enrichment of PDX cells by magnetic-activated cell sorting 
Magnetic-activated cell sorting (MACS) was used for enrichment of small numbers of PDX 
cells from the murine bone marrow. Anti-human NGFR microbeads were used for targeting 
transgenic NGFR
+ 
PDX cells from the entire bone marrow. For this purpose 200 µl of beads 
were added to 10 ml PBE bone marrow suspension. After 45 min of incubation at 4°C under 
rotation, suspension was divided and loaded on two LS column (Miltenyi Biotech, Germany).  
Manufacturer’s instructions were followed for the next washing steps and for the recovery of 
the PDX cells from the columns. 
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3.2.9 Sorting for dormant, drug treated and proliferating PDX cells 
To obtain dormant, drug treated and proliferating PDX cell populations, cells isolated from 
the bone marrow (see 3.2.4) were enriched by MACS (see 3.2.8). Afterwards cell sorting with 
FACS Aria (BD Biosciences, Germany) was performed with similar gating strategies as in 
Figure 6 in the methods. The mCherry transgene in the PDX cells were used as an unique 
marker for PDX cell detection. Dormant PDX cells, which were defined as label retaining 
cells (LRC; see 1.3.1), were CFSE
+
 (see 3.3.4) compared to the CFSE
-
 proliferating cells. 
Therefore, an additional gate on CFSE
+
 cells was used for sorting of LRC. All steps were 
performed at 4°C. The PDX cells were sorted either in FCS for freezing (see 3.3.2), in patient 
medium for single cell RNA-seq with at least 100 cells/µl or in TCL-buffer for bulk RNA-seq 
with the required concentration of 2,000 cells in 80 µl TCL- buffer.  
 
3.3 Ex vivo methods for PDX cells 
3.3.1 Cell counting 
PDX cell numbers were counted with a Neubauer chamber. The cell solution was usually 
diluted 1:100 to count between 100 - 400 cells in all 4 squares of this chamber by using a light 
microscope. Only cells touching the lower and right borders of each square were included to 
the count.  
To differentiate between living and dead cells, 0.4% trypan blue (w/v) were mixed 1:1 (v/v) 
with cell dilutions before counting. Under the microscope living cells appeared colorless 
while dead cells were stained blue. 
Cell concentration was calculated as followed: 
 
                                                                               
 
3.3.2 Freezing  
1x10
7
 PDX cells or 1/3 of the entire bone marrow were frozen in cryotubes with 1 ml fetal 
calf serum (FCS) containing 10% DMSO. For a sensitive freezing, each pellet was 
resuspended in 0.5 ml FCS after centrifugation (400 g, 5 min, RT). Afterwards 0.5 ml 
freezing medium (80% FCS with 20% DMSO) was added dropwise under shaking. Filled 
cryotubes were placed into a freezing container, loaded with isopropyl alcohol, for a cooling 
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rate of 1°C/min, and stored at -80°C for 24 h. For short term storage the cryotubes were kept 
at -80°C and for long-term storage in liquid nitrogen at -196°C.  
 
3.3.3 Thawing   
PDX cells were thawed by the standard protocol from our institute to obtain high viability. 
Frozen cells were defrosted immediately in a 37°C water bath. Under shaking 100 µl DNase 
(1 mg/ml) were added dropwise to the cell suspension. Cell suspensions were transferred to a 
50 ml tube. Within two minutes first 1 ml FCS, then 10 ml PBS with 2% FCS were added and 
finally the suspension was filled up to 30 ml with PBS with 2% FCS. Afterwards the cells 
were centrifuged (400 g, 5 min, RT). 
 
3.3.4 CFSE labeling  
Freshly isolated PDX cells from the spleen of a donor mouse (see 3.2.3) were labeled ex vivo 
with CFSE for detection of dormant cells (LRC) in the next mouse passage. CFSE was a 
fluorescent cell staining dye, which was able to penetrate the cell membrane und bind 
covalently to intracellular molecules. With this covalent binding CFSE was retained in the 
cell.  
1x10
7
 PDX cells were suspended in 10 ml pre-warmed (37 °C) PBS with 0.1% BSA. CFSE 
was suspended in DMSO to a concentration of 5 mM and was added to the cell suspension 
with a final concentration of 10 µM. After 10 min incubation at 37°C, staining was stopped 
by adding five times staining volume of cold RPMI supplemented with 10% FCS, and 
incubated for 5 min on ice. Cells were then centrifuged (400 g, 5min, RT) and resuspended in 
sterile PBS for injection into recipient mice. 
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3.4 Immunostaining of femur cryosections 
3.4.1 Femur preparation for cryosections 
Femurs were treated as follow to allow storage and sectioning. All steps were performed at 
4°C and between all steps femurs were washed with PBS. Freshly isolated femurs of one 
mouse were fixed in 10 ml zinc formalin fixative for 1 day, decalcified with Osteosoft 
(Merck; Germany) for 3 days and finally infiltrated with 30% sucrose PBS solution for 1 day 
before embedding in O.C.T. compound (Sakura; USA). Finally, femurs were stored at -80°C. 
 
3.4.2 Femur cryosections  
Cryosections of decalcified bones were obtained by using the cryostat CM1900UV (Leica; 
Germany) and CryoJane tape transfer system (Leica; Germany). Before sectioning, the 
samples were acclimatized for at least 30 min to the temperature of the cryostat, which was     
-19°C. The section thickness was 7 µm. Each section was captured on an adhesive tape 
window (Leica; Germany) and afterwards put on a CFSA4x slide (Leica; Germany). The 
binding between sections and tape window were broken by UV light from the CryoJane Tape 
transfer system (Leica, Germany) resulting in binding between section and slide. The slides 
could be stored for some days at -20°C. 
 
3.4.3 Immunostaining 
Slides with the cryosections were thawed to room temperature, hydrated with PBS for 10 min 
and blocked with the blocking buffer (PBS with 5% goat serum & 0.1% Tween-20) for 45 
min. The blocking buffer was also used for antibody dilutions and for washing procedures 
(3x5 min) between all the steps. 
The primary antibodies were applied on the sections for 1 day at 4°C in a hydration chamber. 
After washing secondary antibodies were applied for 45 min at room temperature. Sections 
were finally stained with 10 mg/ml DAPI for 15 min and slides were mounted with prolong 
gold antifade mountant (Invitrogen; USA). The stained sections were stored at 4°C.  
Primary antibodies were rabbit-anti-FITC/CFSE (1:100; ThermoFisher; USA) and rabbit-anti-
mCherry (1:100; Abcam; UK). Goat-anti-rabbit antibody conjugated with Alexa 594 (1:500; 
Invitrogen; USA) was used as secondary antibody. 
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3.4.4 Confocal microscopy 
A Leica TCS SP5 II confocal microscope (Leica, Germany) was used to acquire 8-bit images 
of the stained cryosections using the hybrid detectors. With regard to the huge image size, half 
femur was scanned with the objective HCX PL APO LS 20x0.7 IMM UV (Leica; Germany) 
and the function of tile- & Z-Scan. Following settings were chosen to have a high scanning 
speed at the expense of a better resolution and increased noise: 
format = 1024x1024 pixels; speed = 400 Hz; bidirectional scan = on; frame average = 0; 
sequential scan = off 
 
3.4.5 Analysis of PDX localization within femur sections  
The software ImageJ was used for the analysis of the images. A commonly threshold was set 
in the contrast settings to reduce the background noise of all images. Gamma correction was 
never used.  
The endosteal region was defined by a distance as less than 100 µm from the bone matrix 
(Nombela-Arrieta et al. 2013). For determination of the absolute PDX cell numbers in each 
region, mCherry
+
 cells were automatically counted (>10 pixel = one cell). The ImageJ 
function, watershed, was used to separate two overlapping cells. 
The relative amount of PDX cells in the endosteal region was calculated as the absolute PDX 
cell number in the endosteum divided by the absolute PDX cell number in the entire bone 
marrow scan. Mean and standard error were calculated from at least 3 sections from 2 
independent mice. 
To visualize the LRC, which was defined as less than 2% of the PDX population at day 10 
after cell injection (according to FACS data; Ebinger, Özdemir et al. 2016), CFSE signal 
intensity was adapted to the absolute numbers of mCherry
+
 PDX cells from each consecutive 
section. This was done by adjusting CFSE intensity with the 8 bit threshold. 
  
3.5 Analysis of RNA-seq data 
Freshly isolated PDX cells (LRC, PDX MRD cells and their dividing/untreated controls) from 
the bone marrow (see 3.2.4) and frozen patients’ aspirates (see 2.1) were sorted for RNA-seq 
(see 3.2.9) and were handed over to the working group of our cooperation partner Prof. 
Wolfgang Enard (Department Biologie II, LMU, Munich) for preparation of the cDNA library 
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and sending the samples for RNA-seq. In Table 9 all samples are listed which were sequenced 
in this study. Only matched LRC and non-LRC bulk samples were from the same mice.  
 
                                     Table 9: List of sequenced ALL samples 
sample bulk single cell 
ALL-199 LRC 4 - 
ALL-265 LRC 1 15 
ALL-199 non-LRC 4 - 
ALL-265 non-LRC 1 35 
   
ALL-199 MRD cells 14 90 
ALL-265 MRD cells 4 - 
ALL-199 ctrl cells 8 31 
ALL-265 ctrl cells 4 - 
   
patient MRD cells 3 - 
patient diagnosis cells 5 - 
        LRC (label retaining cell) = dormant PDX cells; non-LRC  
        = dividing PDX cells; MRD (minimal residual disease) cells =  
        chemotherapy treated cells; ctrl (control) = untreated cells 
 
Single cell cDNA and library preparation were done with Fluidgm C1 platform (Fluidgm, 
USA) and the bulk RNA-seq preparation was performed by the working group of Prof. Enard. 
The libraries were sent to the Laboratory for Functional Genome Analysis (Gene Center, 
LMU, Munich) for sequencing with Illumina HiSeq1500 (Illumina, USA). RNA-seq data 
were deposited in NCBIS`s Gene Expression Omnibus (GEO) database and is accessible 
through the GEO accession number: GSE83142. Raw count data from all sequencing reads 
were generated by the working group of Prof. Enard (Ebinger, Özdemir et al. 2016) and were 
used for the following analysis in cooperation.  
 
3.5.1 Bioconductor R – DESeq2: from raw counts to fold changes 
The R package DESeq2 was used to make a differential expression (DE) analysis (Love et al. 
2014). For bulk RNA-seq only the cell data sets were taken which obtained at least 1x10
5
 
reads, and for single cell RNA-seq only those with more than 1x10
6
 reads per each cell. 
Log2 fold changes were calculated by using the Wald test. Hierarchical clustering of samples 
was done with the complete linkage based on Euclidian distances of variance stabilizing data 
(VSD) from DE genes. Only the top 500 genes with lowest padj (FDR adjustment) were 
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plotted as heatmap. The reference expression value is the expression average of the control 
cells. 
Principal Component Analysis (PCA) was performed using VSD of the 500 most variable 
genes to display the main sample variance.  
To analyze combined data from all obtained single-cells, count data was normalized 
accounting for batch effects (Risso et al. 2014). For combined LRC signature (ALL-199 & 
ALL-265; top 250 genes with log2 fold change > 1; padj < 0.05) single cell datasets were 
included by summarized gene-wise median read count as one LRC and non-LRC replicate. 
For combined MRD DE genes of both PDX samples, the average of MRD 199 bulk count 
data was created to have identical numbers of MRD 265 bulk samples. 
All used packages in R with the version numbers are listed in 6.3 in the appendix. 
 
3.5.2 Gene Set Enrichment Analysis  
Gene set enrichment analysis (GSEA) was performed using GSEA Desktop Application 
(Subramanian et al. 2005). For ranking all genes, a metric score was calculated and submitted 
to the Pre-RankedGSEA tool, like recommended from the authors: 
 
                                                
 
The statistical significance was determined by 1,000 gene set per mutations. The Molecular 
Signatures Database (MSigDB) (Liberzon et al. 2015) and the KEGG pathways (Kanehisa et 
al. 2012) were used for enrichment terms. Furthermore, published gene signatures from 
patient data were chosen for association with the PDX gene expression profiles. All gene 
signatures contain only upregulated genes. 
 
3.6 Statistics 
All the statistical analysis in this study was calculated with the GraphPad Prism 6 software. 
Two-tailed unpaired t-test was applied to evaluate differences. In case, the standard deviations 
differed significantly in the F-test, Welch´s correction was applied.  
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4 Results 
The two features of dormancy and chemotherapy resistance are the major challenges in the 
conventional acute lymphoblastic leukemia (ALL) treatment. Therefore, the aim of this thesis 
was to characterize dormant and chemotherapy-resistant ALL cells in order to develop novel 
treatment strategies for improving patients’ outcome. Towards this aim, my investigations 
made use of the patient-derived xenograft (PDX) mouse model, as primary dormant and 
chemotherapy-resistant leukemic cells are very low in numbers, difficult to identify in 
biopsies and cannot be cultivated in vitro (see 1.3). 
 
4.1 Preclinical chemotherapy treatment trials in the PDX mouse model 
The first step towards the aim of the thesis was to study chemotherapeutic effects and 
resistance against chemotherapy. Therefore, I established various PDX mouse models using 
different chemotherapy regimens in vivo. 
 
4.1.1 Inducing minimal residual disease (MRD) after chemotherapy 
ALL therapy is based on the excessive use of cytostatic drugs. During and after treatment 
chemotherapy resistance can be detected. Small numbers of leukemic cells remaining after 
therapy and within remission, without signs and symptoms of leukemia, are defined as 
minimal residual disease (MRD). The detection of less than 1% leukemic blasts in the bone 
marrow is termed MRD in the clinics. MRD is the main reason for patients’ relapse and poor 
prognosis (see 1.1.2)(Borowitz et al. 2008; Buckley et al. 2013; Campana. 2010). Due to the 
minute numbers of patients’ MRD cells in the entire bone marrow, no functional research is 
feasible. Thus, I aimed to establish a preclinical model for MRD using patients’ leukemia 
cells growing in mice which, as far as to my knowledge, does not exist as such so far. 
 
The ALL xenograft mouse model is based on the immunocompromised NOD scid gamma 
(NSG) mice (Kamel-Reid et al. 1989; Lee et al. 2007; Liem et al. 2004). NSG mice show 
reduced innate immunity by decreased activity of dendritic cells and macrophages. 
Furthermore, these mice have a disorder in the adaptive immune system by lacking mature T- 
and B-cells in addition to the null mutation in the interleukin 2 receptor gamma chain. These 
characteristics are necessary for the engraftment and growth of human primary material in 
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NSG mice (Ishikawa. 2013; Shultz et al. 2005). In this thesis the two PDX samples, ALL-199 
and ALL-265, from two different ALL patients, were used continuously (see 2.2).  
 
The transgenic PDX samples ALL-199 and ALL-265 were used for the establishment of a 
PDX MRD model (see 2.2). The aim was to mimic patients’ MRD situation as close as 
possible. At diagnosis, patients usually show an advanced state of disease with high tumor 
burden in the bone marrow as clinical symptoms appear late. After initial chemotherapy this 
tumor load is decreased drastically. The defined MRD level of less than 1% blasts in the 
entire bone marrow is often reached (Buckley et al. 2013; Inaba et al. 2013). Thus I aimed at 
mimicking both, high leukemic burden as well as less than 1% MRD blasts after 
chemotherapy, in the PDX MRD mouse model. 
Bioluminescence in vivo imaging for disease monitoring was used to define both disease 
stages in a non-invasive way. In contrast to other methods of disease monitoring like 
measurement of human blasts in mouse blood, imaging is sensitive enough to monitor the 
course of disease even at minor leukemia burden as in MRD (Terziyska et al. 2012; Vick et al. 
2015). 
To demonstrate the correlation of imaging signal and leukemic burden 1x10
6
 thawed or 
freshly isolated  PDX cells from the spleen of a passaging mouse (ALL-199 and ALL-265) 
were injected in several recipient mice (see 3.2.3). The PDX cells were transduced with the 
firefly luciferase reporter gene. The injection of D-Luciferin, the substrate of firefly 
luciferase, induces an enzymatic reaction leading to bioluminescence, which is measured with 
IVIS Lumina II Imaging System (PerkinElmer, USA). With this technique leukemia burden 
was followed in living mice (see 3.2.5).  
In both samples, low imaging signals of a maximum of 2x10
9 
photons per second per cm
2
 per 
steradian (lg photons s
-1
) correlated with less than 1% of PDX cells in the bone marrow. A 
high tumor load with more than 10% of blasts in the isolated bones resulted in high imaging 
signals with at least 1x10
10
 photons per second per cm
2
 per steradian for ALL-265 and 5x10
10
 
photons per second per cm
2
 per steradian for ALL-199 (see Figure 7). In vivo imaging signals 
were reliable and correlated with high significance with the percentage of PDX cells in the 
bone marrow. Thus, bioluminescence in vivo imaging allows monitoring the entire tumor load 
spectrum required for establishing a PDX MRD model. 
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Figure 7: High correlation of in vivo imaging signal and PDX cell percentage in the bone marrow.  
The PDX samples ALL-199 and ALL-265 were transgenic for the firefly luciferase. Before the bone marrow 
was isolated, the mice were imaged for in vivo bioluminescence. The percentage of PDX cells in the bone 
marrow, based on FACS data, shows a high correlation with the in vivo imaging results in both samples.  
 
 
For the PDX MRD mouse model a reduction of high tumor load to MRD level was necessary 
and I aimed to reach this by using a polychemotherapy, which is defined as the use of at least 
two different cytostatic drugs (Lippert et al. 2014). Such treatment strategies are also pursued 
in patients. To establish polychemotherapy, suitable for mice and close to the situation in the 
clinics, pre-experiments were performed with 4 cytostatic drugs to test their tolerance in NSG 
mice and effects on leukemia growth. All drugs, which are commonly used in ALL patients’ 
therapy, were administered once a week and the effects were determined by in vivo imaging. 
The test series indicated that Vincristine (VCR) and Cyclophosphamide (Cyclo) were better 
tolerated by NSG mice and were more effective than Etoposide or Dexamethasone as shown 
by inhibition of tumor growth (see Appendix Figure 37). Treatment with the same drug 
concentration over several weeks without any significant weight loss (<10% after therapy 
start) of mice was defined as a good tolerated drug. Etoposide, which showed high leukemia 
burden reduction, was not considered for a long-term trial due to high toxicity (see Table 10). 
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Table 10: Summary of the tested cytostatic drugs according to tolerance in NSG mice and effects on 
leukemia growth inhibition over several weeks of treatment 
drug 
tolerance in  
NSG mice 
effect in  
PDX ALL cells 
Vincristine high (<0.5 mg/kg) high  
Cyclophosphamide high (<100 mg/kg) low 
Etoposide 
low (30-50 mg/kg) 
 
low (< 10 mg/kg) 
high 
 
low 
Dexamethasone low (2 mg/kg) no effect 
low tolerance = mice had to be sacrificed within 1 week due to high weight loss (>10 % of weight loss since 
therapy start);   
 
 
To mimic patients’ long-term treatment, one additional criterion was the moderate decrease of 
leukemia burden for several weeks. For this reason the concentrations of VCR and Cyclo 
were optimized with respect to a combined therapy over several weeks. The used 
concentrations matched also to patients’ dose in the clinics (see Table 8 in Methods). 
These experiments revealed that a treatment consisting of 0.25 mg/kg VCR (i.v. once per 
week) combined with 100 mg/kg Cyclo (i.p. once per week, two days after VCR) is well 
tolerated in NSG mice and effectively reduces tumor burden with a suitable kinetic. This 
chemotherapy scheme was used in all further experiments in both samples (see Figure 8). 
 
 
 
Figure 8: Scheme for generating PDX MRD cells in vivo.  
1x10
6
 freshly isolated or thawed transgenic PDX cells were injected into each mouse. PDX cells were positive 
for the following transgenes: mCherry, truncated NGFR and firefly luciferase. Leukemia engraftment and 
therapy effects were followed by in vivo imaging. After reaching high tumor load chemotherapy was initiated. 
VCR (0.25 mg/kg; i.v.) and Cyclo (100 mg/kg; i.p.) were injected weekly as single dose for a mono- or 
combination therapies. The untreated control group received PBS. After 2 or 3 weeks, depending on the sample, 
therapy was stopped and the mice were analyzed. Adapted from (Ebinger, Özdemir et al. 2016). 
 
 
Next, we aimed to induce MRD with the established polychemotherapy protocol in order to 
isolate PDX MRD cells from the animals. Towards this aim, PDX cells were grown to an 
advanced disease stage as confirmed by in vivo imaging. Tumor burden of mice was analyzed 
at that time point and indicated approximately 40% blasts in the bone marrow. For treatment, 
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a single dose of each cytotoxic drug was injected weekly as mono- or combination therapies 
(see 3.2.7). Imaging was performed before each new treatment series. Figure 9A displays the 
raw in vivo imaging data as example for treatment effects in ALL-199. The untreated control 
group showed an increased imaging signal over 7 days after treatment start. This group had to 
be sacrificed between days 7 and 10 due to advanced leukemia, as indicated by the enlarged 
spleens at day 7. All treated groups indicated continuously decreasing signal intensities. The 
combination therapy showed higher reduction of leukemia cells compared to monotherapies. 
Figure 9B summarizes all imaging data over time of each sample and therapy group. 
To determine tumor burden and to isolate PDX cells bone marrow of mice was analyzed after 
sacrificing. The untreated control group had to be taken down with approximately 60% of 
blasts after 1 week of therapy start for ALL-199 or after 2 weeks for ALL-265. Cyclo 
treatment (100 mg/kg) alone retarded the leukemia growth of ALL-199 and reduced the 
leukemia load to 10% of ALL-265 cells in the bone marrow after 2 weeks of treatment. In 
comparison, VCR treatment (0.25 mg/kg) reduced drastically the leukemia load to a level of 
approximately 1% blasts in both samples. ALL-199 (0.5% of blasts after two treatment 
rounds) was more sensitive to VCR than ALL-265 (1.8% of blasts after three treatment 
rounds; see Figure 9C). 
MRD level of less than 1% blasts in the bone marrow was only obtained with combination 
therapy of VCR and Cyclo for both PDX samples. It was even possible to reduce the 
leukemia load to blast levels of around 0.1% after 2 or 3 weeks of treatment, depending on the 
PDX sample. Thus, ALL-199 and ALL-265 showed a similar treatment response in 
combination therapy, but differed in monotherapies (see Figure 9C). 
 
In the following VCR and Cyclo treated PDX cells at MRD level are defined as PDX MRD 
cells. From each mouse with a level of 0.1% blasts, approximately 40,000 PDX MRD cells 
were isolated from the entire bone marrow. 
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Figure 9: MRD level is achieved for both PDX samples with the combination therapy. 
One representative experiment for each PDX sample is shown with at least 3 and maximum 8 mice per group. 
VCR (0.25 mg/kg; i.v.) and Cyclo (100 mg/kg; i.p.) were injected weekly as single dose for mono- or 
combination therapies. The untreated control group received PBS. MRD level was defined with less than 1% 
PDX cells in the bone marrow (grey background). (A) Raw in vivo imaging data of three representative mice per 
group of ALL-199 are shown. Units in rainbow color scales are photons per second per cm
2
 per steradian 
(photons s
-1
 cm
2-1
 sr
-1
). (B) The summarized in vivo imaging data over time shows the leukemia burden before 
and during treatment. (C) After sacrificing the mice, the percentages of PDX cells in the bone marrow were 
determined. The left panel summarizes the data for ALL-199 and the right panel the data for ALL-265. 
Statistical significances were calculated using two-tailed unpaired t-test (*p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001). Adapted from (Ebinger, Özdemir et al. 2016). 
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Taken together, a PDX MRD mouse model for two PDX samples was established mimicking 
the situation of patients with MRD. With VCR and Cyclo combination therapy, high leukemia 
load was reduced more than 100-fold to the MRD level of 0.1% PDX cells in the bone 
marrow. 
 
4.1.2 Different effects in long-term VCR treatment in PDX samples  
After establishment of the PDX MRD model, the effect of long-term VCR treatment was 
analyzed in both ALL samples according to development of chemotherapy resistance. The 
combination therapy with VCR and Cyclo was too stressful for mice after 3 weeks of 
treatment as the mice started to lose continuously weight. Therefore, monotherapy with VCR, 
which was more efficient than Cyclo, was used for long-term studies (see Figure 9).  
After inducing leukemia with ALL-199 and ALL-265 and reaching high tumor load, 
treatment with VCR (0.5 mg/kg), one dose per week, was initiated. Compared to the 
established PDX MRD model the concentration of VCR was increased to the highest tolerable 
dose in monotherapy in order to raise the chemotherapeutic stress in the PDX cells (see Table 
10). Both ALL samples showed a very different VCR sensitivity in long-term treatment (see 
Figure 10). After 4 weeks VCR treatment was stopped in ALL-199 due to a strong reduction 
of leukemic burden as determined by in vivo imaging. Suspending the VCR treatment in the 
ALL-199 sample led to the regrowth of the leukemia. In contrast, ALL-265 was resistant to 
VCR chemotherapy. Over a course of 10 weeks VCR treatment, the leukemia load decreased 
only slowly but never reached MRD level. The following low increase in in vivo imaging 
signal after this time point indicated an outgrowth of leukemia. After sacrificing the mice of 
the VCR ALL-265 group, the entire bone marrow contained 2.5% of PDX cells. 
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Figure 10: Long-term treatment with VCR shows different effects in PDX samples. 
Both PDX ALL samples were treated weekly with a single dose of 0.5 mg/kg VCR (i.v.). ALL-199 was sensitive 
for VCR in contrast to ALL-265, in which a resistance to VCR was observed. Adapted from (Ebinger, Özdemir 
et al. 2016). 
 
This experiment confirmed the observation that ALL-199 is more sensitive to VCR treatment 
than ALL-265 (see Figure 10). VCR reduced ALL-199 to very low cell numbers and easily 
reached MRD level. However, the remaining PDX ALL cells proliferated quickly after 
withdrawal of VCR. In contrast, a VCR-resistant population of ALL-265 arose after a long-
term therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                           Results 
48 
 
4.1.3 PDX MRD cells reveal certain chemotherapy resistance 
The next question was, whether the PDX MRD cells acquired functional changes by treatment 
influencing homing efficiency and chemotherapy sensitivity compared to untreated control 
cells.  
To address this question, PDX MRD cells and untreated control cells were freshly isolated 
from the bone marrow of the first treatment round and PDX cells were enriched specifically 
using the mCherry transgene. All MRD cells of all mice in the MRD group (VCR & Cyclo;   
n = 6) were merged due to low cell numbers. The same was performed with the control group 
(n = 3). At the end the sorted cells were injected in 8 recipient mice per group with equal cell 
numbers of 4x10
4 
cells (see Figure 11). 
 
 
Figure 11: Scheme for re-passaging and retreatment of PDX MRD cells in ALL-265.  
After first round of treatment with combination therapy with VCR (0.5 mg/kg; i.v.) and Cyclo (100 mg/kg; i.p.) 
for 3 weeks and reaching the MRD level, PDX cells were isolated from the bone marrow. Due to low MRD cell 
numbers, PDX cells of all 6 mice of the VCR & Cyclo group and PDX cells of the 3 mice of the untreated 
control group were combined in each case and 4x10
4
 of the sorted MRD or control cells were injected into each 
recipient mice per group (n=8) for the second treatment round. Upon engraftment cells were allowed to grow out 
to a high tumor load, potential differences in homing efficiency were determined and both groups were treated 
with the same combination therapy to investigate changes in treatment sensitivity. 
 
In vivo imaging was performed to investigate potential differences in homing and engraftment 
between the untreated control cells and the PDX MRD cells from the first treatment round. 
No significant differences for homing and engraftment were observed between the two groups 
(see Figure 12A).  
After reaching high tumor load, combination therapy with VCR and Cyclo was repeated for 
the MRD as well as the untreated control group from the first round. The treatment was 
initiated by reaching 50% PDX cells in the bone marrow (see Figure 12B). After 3-weeks of 
combination therapy, 0.1% of PDX cells in the bone marrow in the control group and 0.3% in 
the MRD group were reached. A 2.5-fold higher amount of PDX cells was isolated from the 
MRD group (2.2x10
5
 cells) compared to the control group (0.9x10
5
 PDX cells), which 
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received therapy for the first time (see Figure 12C). These significant differences were also 
observed in the in vivo imaging.  
 
 
Figure 12: ALL-265 PDX MRD cells re-engraft in recipient mice and display higher chemotherapy 
resistance compared to the control group. 
4x10
4
 of ALL-265 untreated or PDX MRD cells were injected into each mouse for both groups (n=8). After 
reaching high leukemia load, the MRD group as well as the untreated control group was treated with the 
combination therapy of 0.5 mg/kg VCR (i.v.) and 100 mg/kg Cyclo (i.p.) as one passage before for the PDX 
MRD cells.  (A) The summarized in vivo imaging data over time shows the leukemia burden before and during 
treatment. After sacrificing the mice, the percentage (B) and the absolute numbers (C) of PDX cells in the bone 
marrow were determined. Statistical significance was calculated using two-tailed unpaired t-test (ns = no 
significane, **p<0.01). 
 
In summary, no differences in homing and engraftment were observed between the PDX 
MRD and control cells. Three weeks of combination therapy had no effect on PDX MRD 
cells for the outgrowth of leukemia in the next passage compared to the untreated control 
group.  
However, the chemotherapy sensitivity was significantly different between the both groups. In 
the second treatment round, the MRD group was more resistant to combination therapy than 
the control group. The treatment in the first passage had an influence in the next therapy 
round. The PDX MRD cells acquired a certain drug resistance after the first combination 
therapy compared to the control group. In conclusion, an innovative mouse model of in vivo 
induced chemotherapy resistance was established. 
 
Taken together, I developed the worldwide first preclinical PDX mouse model of MRD and a 
model of long-term treatment using VCR. I could show that PDX MRD cells develop certain 
chemotherapy resistance after treatment in mice. 
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4.2 Localization of dormant and chemotherapy-resistant PDX cells in the 
bone marrow 
Dormancy and chemotherapy resistance in ALL is increasingly attributed to influence of the 
bone marrow environment (see 1.1.3) (Schepers et al. 2015). Furthermore, in our institute this 
concept was confirmed by the previously established label retaining cell (LRC) mouse model. 
In the LRC mouse model PDX cells were labeled with the fluorescent proliferation marker 
CFSE before cell injection into NSG mice. CFSE signal is halved by every cell doubling. A 
minute ALL subpopulation did not lose any CFSE signal over time. The retaining CFSE 
signal is associated with no cell division and consequently with dormancy. These dormant 
PDX cells (LRC) were chemotherapy-resistant in vivo, but chemotherapy sensitive in vitro 
like dividing PDX cells (non-LRC). Furthermore, a high plasticity within the both populations 
was observed. LRC and non-LRC were able to engraft in the next passage and showed the 
identical engraftment pattern of dormant and dividing cells (see 1.3.1; Ebinger, Özdemir et al. 
2016). 
These findings led to the hypothesis that the localization of LRC and PDX MRD cells in the 
bone marrow is crucial to gain the challenging features of dormancy and drug resistance. 
Therefore, my next aim was to identify the localization of dormant and chemotherapy-
resistant leukemic PDX cells within the bone marrow. 
 
4.2.1 After engraftment, the two PDX samples show different localization patterns 
First, the bone marrow localization of PDX samples ALL-199 and ALL-265 was investigated 
directly after PDX cell injection and engraftment. The mCherry reporter gene, which is 
expressed in both PDX samples, allows their unambiguous identification and visualization in 
the femurs of transduced mice. The schematic outline of the protocol is shown in Figure 13. 
To identify the localization of the PDX cells within the bone marrow, I newly established 
generating cryosections of femurs. Unfortunately, the fixation step of the femur preparation 
protocol destroyed the mCherry signal. For this reason, an antibody staining against mCherry 
had to be established for the detection of PDX cells. In contrast to the mCherry signal, the 
CFSE fluorescence signal of the PDX cells was still detectable after fixation. Therefore, 
mCherry
+
 CFSE
+ 
PDX cells were used to establish the mCherry antibody staining while the 
CFSE signal was used as a positive control (see Figure 13). At day 3 after cell injection all 
PDX cells were still CFSE
+
.  
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A high correlation between the CFSE and the mCherry antibody signal was observed in these 
femur sections. The mCherry signal was always detectable in CFSE
+
 cells in the bone marrow 
(see Figure 38 in the appendix). The negative controls were femur sections without any PDX 
cell injection or with mCherry
-
 PDX cells. These sections were completely negative for 
mCherry antibody staining. 
 
After establishing the mCherry antibody staining for PDX cell detection in the bone marrow, 
an engraftment kinetic of leukemia growth was performed. Therefore, freshly isolated PDX 
cells from the spleen of a donor mouse were labeled with CFSE and 1x10
7
 CFSE
+
 mCherry
+ 
PDX cells were injected into recipient mice. At days 3, 7, 10 and 14 after cell injection one 
mouse was sacrificed at each time point and the localization of the PDX cells was analyzed 
for both samples ALL-199 and ALL-265 (see Figure 13). 
 
                   
Figure 13: Scheme for the PDX cell localization in femur sections during engraftment. 
mCherry
+
 PDX cells were freshly isolated from the spleen of the donor mice and labeled with CFSE ex vivo. 
Recipient mice were injected with 10
7
 CFSE
+
 mCherry
+
 PDX cells into the tail vein. After several days the 
femurs were taken for histological analysis. Adapted from (Ebinger, Özdemir et al. 2016). 
 
The engraftment pattern was similar for all time points of each sample. PDX ALL-199 cells 
were randomly distributed in the bone marrow during engraftment (see Figure 14), whereas 
the sample ALL-265 engrafted close to the bone matrix (see Figure 15). 
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Figure 14: ALL-199 PDX cells engraft randomly in the femur. 
ALL-199 PDX cells were positive for mCherry and were visualized by mCherry antibody staining shown in a 
kinetic at different days after cell injection. The nuclei were counterstained with DAPI. The left magnification 
box of each time point shows the area around the endosteum and the right magnification box of each time point 
shows perivascular regions. (red = mCherry; blue = DAPI) 
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Figure 15: ALL-265 PDX cells engraft primarily in endosteal regions. 
ALL-265 PDX cells were positive for mCherry and were visualized by mCherry antibody staining shown in a 
kinetic at different days after cell injection. The nuclei were counterstained with DAPI. The left magnification 
box of each time point shows the area around the endosteum and the right magnification box of each time point 
shows perivascular regions. (red = mCherry; blue = DAPI) 
 
Femur sections were analyzed with the software ImageJ to quantify PDX cells localized in the 
endosteal region at day 3, 7 and 10 after cell injection. At day 14 after cell injection the PDX 
cell density was too high for precise quantification. 
For the PDX cell localization of both samples similar kinetics were determined. At day 3 after 
cell injection the majority of the PDX cells were close to the endosteum. The region around 
the bone matrix is called endosteum or endosteal niche (see Figure 2 in the introduction). The 
endosteum is defined as the region with a distance of less than 100 µm from the bone matrix 
(Nombela-Arrieta et al. 2013). At day 3 after cell injection approximately 50% of ALL-199 
PDX cells and approximately 70% of ALL-265 PDX cells localized in this region. Until day 
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10 the percentage of PDX cells in the endosteum decreased significantly (see Figure 16). 
However, ALL-265 engraftment remained more associated to the endosteal region than ALL-
199 cells. 
 
                          
Figure 16: The PDX samples ALL-199 and ALL-265 show a similar distribution kinetic in the endosteum 
during engraftment. 
Quantification of PDX cells in femur sections was performed using ImageJ. The endosteum is defined as the 
region with a distance of less than 100 µm from the bone matrix. At least 2-3 sections from both femurs of 2 
mice per data point were analyzed. Statistical significance was calculated using two-tailed unpaired t-test 
(*p<0.5, **p<0.01). Adapted from (Ebinger, Özdemir et al. 2016). 
 
The PDX samples showed a different engraftment pattern but a similar distribution kinetic 
over time in the endosteum. At day 3 after cell injection, most PDX cells were localized to the 
endosteum in both samples. In the following days the percentage of PDX cells in the 
endosteal region decreased constantly. However, ALL-265 cells were closely localized to the 
endosteal region at all-time points. In contrast, ALL-199 cells exhibited a more random 
engraftment pattern in the bone marrow. 
 
4.2.2 Enhancing the CFSE signal by antibody staining 
One hypothesis is that the dormant and drug resistant LRC and PDX MRD cells gain these 
features through a specific localization in the femur. Therefore, the next aim was to identify 
the localization of dormant PDX cells during engraftment in the LRC mouse model (see 
Figure 4 in the introduction). The fluorescent cell staining dye CFSE was used as proliferation 
marker for identification of dormant LRC (CFSE
+
 PDX cells). With each cell division the 
CFSE intensity is reduced by half and consequently dividing PDX cells lose their CFSE 
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signal. Only non-dividing, dormant PDX cells keep the CFSE over time (Ebinger, Özdemir et 
al. 2016).  
However, the CFSE signal at time points later than day 3 after cell injection was too weak for 
detection by confocal microscopy. Additionally, high autofluorescence signal in the spectrum 
of the CFSE signal (green light spectrum around λ=500 nm) made the detection of the CFSE 
signal complicated. This phenomenon was described in fixed bone marrow sections by Lo 
Celso and colleagues (Lo Celso et al. 2007). To increase the sensitivity of the experiment, a 
CFSE antibody staining had to be established allowing the detection of LRC within femur 
sections later than 3 days after cell injection.  
The chemical structures of CFSE and FITC are very similar. Thus, a FITC-antibody (Thermo 
Fisher Scientific, USA) was tested for CFSE antibody staining (Willfuhr et al. 1989). Similar 
to the validation of the mCherry antibody staining, femur sections of day 3 after CFSE
+
 PDX 
cell injection were used. The high CFSE signal at day 3 functioned as a positive control for 
the CFSE antibody staining. A secondary antibody, binding the primary FITC/CFSE 
antibody, was conjugated with the fluorophore Alexa 594 in order to separate the fluorescence 
spectra of the CFSE and the CFSE antibody signal.  
The signal of the CFSE antibody staining correlated with the CFSE signal (see Figure 17). 
Femur section without any PDX cells or with CFSE
-
 PDX cells used as negative controls, 
were indeed negative.  
 
 
Figure 17: High correlation of the CFSE antibody signal with the CFSE signal. 
Femur sections of day 3 after CFSE
+
 PDX cell injection were stained with the CFSE antibody (purple). The 
CFSE signal (green) served as positive control for the staining. The nuclei were counterstained with DAPI 
(blue). 
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In femur sections of day 7 after cell injection the problem of low CFSE signal was obvious 
(see Figure 18). Without signal amplification of CFSE, LRC were not detectable in femur 
sections at later time points than 3 days after cell injection. Therefore, the CFSE antibody 
staining was necessary and I used the FITC/CFSE antibody to visualize low numbers of LRC 
in the femur with high specificity and sensitivity. 
 
 
Figure 18: CFSE antibody staining is sensitive enough to detect CFSE
+
 PDX cells in femur sections later 
than 3 days after cell injection. 
Femur sections of day 7 after CFSE
+
 PDX cell injection were stained with the CFSE antibody (purple) in order 
to amplify the CFSE signal (green) for further analysis. 
 
 
4.2.3 LRC are localized in the endosteum  
After establishment of the required CFSE antibody staining for signal amplification, the 
visualization of LRC was feasible in femur cryosections. Freshly isolated PDX cells from the 
spleen of a donor mouse were labeled with CFSE ex vivo and 10
7 
CFSE
+
 PDX cells were 
injected into each recipient mouse (see Figure 13). At day 10 after cell injection most PDX 
cells proliferate in the bone marrow as reasoned from the decreased CFSE labeling. At this 
time point LRC were identified by their high CFSE signal in FACS analysis, and defined as 
less than 2% of the entire PDX population or as approximately 0.01% of the entire cells in the 
bone marrow (see Table 11 in the appendix). A meaningful quantification at later time points 
was not possible due to continuously decreasing numbers of LRC in the bone marrow. Hence 
LRC localization was analyzed at day 10 after cell injection via CFSE stainings.  
Furthermore, it was not possible to stain one section simultaneously for LRC (CFSE staining) 
and PDX cells (mCherry staining) as both antibodies had the same species type and required 
consequently the identical secondary antibody. Thus two consecutive sections were performed 
and stained either for PDX cells or for LRC. 
The endosteal region of the bone marrow was described as the niche for dormancy as 
demonstrated for hematopoietic stem cells (HSC) (Haylock et al. 2007; Morrison & 
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Spradling. 2008). Therefore, the hypothesis was that LRC, showing a quiescent phenotype, 
were localized near to the endosteum. 
 
 
Figure 19: In both PDX samples, ALL-199 & ALL-265, LRC are concentrated to the endosteum 
compared to proliferating PDX cells. 
Consecutive femur sections of day 10 after CFSE
+
 PDX cell injection were stained with antibodies either for 
mCherry (PDX cell marker, red) or CFSE (LRC marker, green). The endosteum is defined as the region with a 
distance of less than 100 µm from the bone matrix. The left magnification box of each femur scan shows 
perivascular regions and the right magnification box of each femur scan shows the area around the endosteum. 
The nuclei were counterstained with DAPI (blue). Adapted from (Ebinger, Özdemir et al. 2016). 
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In both PDX samples LRC localized close to the endosteum, whereas PDX cells were 
detected in the entire bone marrow (see Figure 19). However, the ALL-265 PDX cells were 
preferably localized in the endosteal region, as already shown in Figure 15. Besides, ALL-199 
exhibited a higher percentage of LRC at day 10 after cell injection than ALL-265 (see Figure 
19). This observation was also demonstrated by FACS analysis. In ALL-199 ten times more 
LRC are present than in ALL-265 at day 10 after cell injection (see Table 11 in the appendix; 
Ebinger, Özdemir et al. 2016). 
All consecutive sections stained for mCherry and CFSE were analyzed with the software 
ImageJ to quantify the amount of cells localized in the endosteum. Approximately 30% of 
ALL-199 PDX cells and 50% of ALL-265 PDX cells were located close to the endosteal 
region as already shown in Figure 16. Both PDX samples showed a complete different 
tendency to the endosteum during engraftment. However, 70% of LRC of both samples were 
localized to the endosteum (see Figure 20).   
 
                                       
Figure 20: In both PDX samples significantly more LRC are localized in the endosteum compared to the 
entire PDX cell population. 
Quantification of all consecutive femur sections, stained either for mCherry (PDX cells) or CFSE (LRC), at day 
10 after cell injection was performed with ImageJ. At least 3 sections from both femurs in 2 mice were analyzed. 
Endosteal region was defined as less than 100 µm to the bone matrix. Statistical significance was calculated 
using two-tailed unpaired t-test (***p<0.001, ****p<0.0001). Adapted from (Ebinger, Özdemir et al. 2016). 
 
Taken together, the hypothesis, that LRC are preferably localized in the endosteum, was 
confirmed. In ALL-199 as well as in ALL-265 the critical subpopulation of dormant PDX 
cells (LRC) preferably localized close to the endosteum. Although the rate of engrafted PDX 
cells differed significantly within both samples, LRC localization to the endosteal region was 
similar for ALL-199 and ALL-265 at day 10 after cell injection.  
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4.2.4 PDX MRD cells are localized randomly in the bone marrow  
Next to dormancy, chemotherapy resistance is the second challenging feature of patients’ 
MRD in clinics. The importance of the bone marrow environment of chemotherapy-resistant 
leukemic cells was shown in various studies (see 1.1.3). Leukemic cells interact with the bone 
marrow microenvironment in order to survive chemotherapy (Boyerinas et al. 2013; Duan et 
al. 2014). To the best of our knowledge the localization of MRD cells of B-ALL was not 
investigated so far. Consequently, I next analyzed the localization of chemotherapy-resistant 
PDX MRD cells in the bone marrow.  
The endosteal region provided a niche for dormant PDX ALL cells during engraftment (see 
4.2.3 and Figure 19). However, cytostatic drugs can lead to an altered microenvironment in 
the bone marrow and the chemotherapy induced environmental changes are misunderstood 
(Wang et al. 2006). 
To obtain femurs of chemotherapy treated blasts at MRD level, mice were treated with a 
combination therapy of VCR and Cyclo after reaching high tumor load. The therapy was 
administered for 2-3 weeks depending on the PDX sample as previously described in the PDX 
MRD model (see 4.1.1). At MRD level of around 0.1% blasts in the bone marrow, mice were 
sacrificed and femurs were prepared for bone marrow sectioning (see Figure 21). PDX MRD 
cells were positive for the transgenic mCherry and therefore suitable for mCherry antibody 
staining. 
 
 
Figure 21: Scheme for generating PDX MRD cells for localization studies in femur sections. 
1x10
6
 freshly isolated or thawed transgenic PDX cells were injected into each mouse. PDX cells were positive 
for the following transgenes: mCherry, truncated NGFR and firefly luciferase. Leukemia engraftment and 
therapy effects were followed by in vivo imaging. After reaching high tumor load chemotherapy was initiated. 
VCR (0.25 mg/kg; i.v.) and Cyclo (100 mg/kg; i.p.) were injected weekly as combination therapy. The untreated 
control group received PBS. At MRD level of about 0.1% blasts in the bone marrow after 2-3 weeks of 
treatment, mice were sacrificed and the femurs were analyzed by staining for transgenic mCherry which is 
exclusively expressed by PDX cells. 
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After a long-term combination therapy with VCR and Cyclo the remaining PDX MRD cells 
of both samples, ALL-199 and ALL-265, were distributed randomly in the femoral bone 
marrow. No distinct morphological areas for PDX MRD cell accumulation were observed 
(see Figure 22). 
 
 
Figure 22: ALL-199 and ALL-265 PDX MRD cells are randomly distributed in the femur after 
combination therapy. 
PDX MRD cells (less than 0.1% blasts in bone marrow after VCR and Cyclo treatment) were positive for 
mCherry and were detected by specific antibody staining (green = mCherry signal). The left magnification box 
of each PDX sample shows perivascular regions and the right magnification box of each PDX sample shows the 
area around the endosteum. The nuclei were counterstained with DAPI (blue).  
 
ImageJ was used for the analysis of the bone marrow scans and revealed that only 30% of the 
PDX MRD cells were localized close to the endosteum after the combination therapy with 
VCR and Cyclo. This PDX MRD population showed a sample independent distribution 
similar to the LRC. In ALL-199 no difference in localization pattern of engrafted PDX cells 
and PDX MRD cells was observed. In contrast, engrafted PDX ALL-265 cells localized 
closer to the endosteum than the chemotherapy treated MRD cells (see Figure 23). 
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Figure 23: Less PDX MRD cells are localized in the endosteum than LRC or engrafted PDX cells after 
combination chemotherapy. 
Quantification of femur sections, stained for mCherry at MRD level of less than 0.1% blasts in the bone marrow, 
was performed with ImageJ. At least 2 sections from both femurs in 4 mice were analyzed. Endosteal region was 
defined as less than 100 µm to the bone matrix. For a better overview the quantification of engrafting PDX cells 
and LRC at day 10 after cell injection was added (see Figure 20). Statistical significance was calculated using 
two-tailed unpaired t-test (ns = no significance, ***p<0.001, ****p<0.0001). 
 
In summary, the PDX samples ALL-199 and ALL-265 exhibited a complete different 
engraftment pattern in the bone marrow. Both PDX samples own a different affinity to the 
endosteum during leukemia growth. ALL-199 PDX cells engrafted randomly in the bone 
marrow and ALL-265 PDX cells exhibited an engraftment concentrated to the endosteum. 
However, the challenging (sub)-populations like LRC and PDX MRD cells showed similar 
localization patterns. The LRC accumulate to a higher degree in the endosteum compared to 
engrafted PDX cells. The PDX MRD cells are less concentrated to this area and are even 
randomly distributed within the bone marrow.  
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4.3 Gene expression profiles of dormant and chemotherapy-resistant PDX 
samples 
The LRC and PDX MRD cells are characterized by the clinically challenging features of 
dormancy and chemotherapy resistance. Both populations depict a high plasticity in 
functional studies. They have the capacity to engraft in the next passage but are not enriched 
in stemness according to self-renewal frequency as compared to control cells (1.3.1 and 
4.1.3). During one passage in mice the dormant LRC and chemotherapy treated PDX MRD 
cells differ highly from the proliferating untreated control cells. 
It is very likely that dormant and proliferating PDX cells differ in their gene expression 
patterns. One method to determine the differences in gene expression is RNA-seq. The 
greatest advantage of RNA-seq compared to microarray is the accurate detection of 
differently expressed genes (especially with low expression levels) due to the sequencing at 
nucleotide level. In contrast, microarrays have a high false-positive rate because of unspecific 
nucleotide binding to the oligos on the microarray chip (Wang et al. 2014; Zhao et al. 2014). 
 
Gene expressions of LRC, PDX MRD cells and the proliferating untreated control cells were 
determined by RNA-seq. Therefore, the mRNA of these PDX cells were isolated as bulk or 
single cell, and were sequenced with Illumina HiSeq1500 (Illumina, USA). Gene expression 
profiles (GEP) of LRC and PDX MRD cells were obtained by direct comparison of the gene 
expressions between these challenging PDX cells and their proliferating untreated controls. A 
detailed analysis of the RNA-seq data was performed with the GEP in order to improve our 
understanding according the challenging features of dormancy and chemotherapy resistance. 
 
RNA-seq of the PDX cells was performed by our cooperation partner Prof. Wolfgang Enard 
and colleagues (Department Biologie II, LMU, Munich). After alignment of sequencing reads 
the obtained raw counts were forwarded to me for further bioinformatic analysis under 
supervision of our cooperation partner (see 3.5). 
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4.3.1 Gene expression profiles of LRC 
First, GEP of LRC were obtained and analyzed in order to gain new insights into the observed 
reversible dormancy in the LRC mouse model. ALL-199 and ALL-265 PDX cells were 
isolated freshly from the spleen of the donor mice and labeled ex vivo with CFSE before 
injection into recipient mice. LRC and non-LRC were obtained from isolated bone marrow of 
the recipient mice approximately 14 days after PDX cell injection (see Figure 24). At this 
time point less than 0.05% of the PDX population consisted of LRC in both samples (see 
Table 11 in the appendix). In addition to the mCherry reporter gene, the PDX cells were also 
transduced for the truncated cell surface protein NGFR. Both transgenes in the PDX cells 
were used for the enrichment of the PDX population from the murine bone marrow. By using 
the NGFR transgene for magnetic-activated cell sorting (MACS) enrichment and the mCherry 
transgene for fluorescence-activated cell scanning (FACS) enrichment, a fast and effective 
sorting of LRC, CFSE
+
 PDX cells, and non-LRC, CFSE
-
 PDX cells, was feasible (see 3.2.9; 
Ebinger, Özdemir et al. 2016). At least approximately 2,000 LRC were harvested from the 
entire bone marrow from both samples (see Table 11 in the appendix). This amount is 
sufficient to perform RNA-seq.  
The freshly isolated and enriched PDX cells were sorted directly either into lysis buffer for 
bulk RNA-seq or into patient medium for single cell RNA-seq (see 3.2.9). The laboratory of 
our cooperation partner Prof. Enard prepared the RNA libraries and all steps necessary for 
RNA-seq. 
 
              
Figure 24: Scheme for preparation of LRC and non-LRC for single cell and bulk RNA-seq.  
Freshly isolated PDX cells from the spleen of a donor mouse were labeled with CFSE ex vivo. Approximately 
1x10
7
 CFSE
+
 PDX cells were injected into the recipient mice. 14 days after cell injection the bone marrow was 
isolated. The PDX cells were enriched by using the NGFR and mCherry transgenes for MACS and FACS 
enrichment, and  sorted for LRC and non-LRC either 1,000 cells in 10 µl patient medium for single cell RNA-
seq or 2,000 cells in 80 µl in TCL-buffer for bulk RNA-seq. Adapted from (Ebinger, Özdemir et al. 2016). 
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4.3.1.1 GEP of LRC are clearly distinguished from non-LRC  
The analyzed RNA-seq raw counts were depicted as a heatmap with hierarchical clustering 
and as a principal component analysis (PCA). This was performed in R using the DeSeq2 
package (see 3.5.1). The differences between the GEP of LRC and non-LRC were highlighted 
by these two different visualization tools.  
In a heatmap the most differentially regulated and significant genes are plotted for each 
sample. The disparate color patterns visualize the differences in the GEP of the compared 
populations. In contrast, PCA is a statistical procedure to sum up variables from each sample 
by reducing the dimension. The main purpose of the PCA is the analysis of data to identify 
patterns of different GEP (Raychaudhuri et al. 2000). 
 
 
Figure 25: GEP of ALL-265 LRC and non-LRC are distinct in single cell RNA-seq. 
For each LRC and non-LRC sample, PDX cells of one mouse was sorted for single cell RNA-seq. (A) 
Hierarchical clustering and gene expression heatmap across the 500 most differentially expressed genes (padj < 
0.01) in 15 LRC and 35 non-LRC single cells were performed. Values are plotted relative to the average of non-
LRC. (B) Principal component analysis (PCA) of the 500 most variable genes in all 50 single cells is shown. 
Each dot indicates a single cell. Adapted from (Ebinger, Özdemir et al. 2016). 
 
Single cell RNA-seq was performed for the LRC sample ALL-265. GEP for 15 single cell 
LRC and 35 single cell non-LRC were obtained. In the heatmap the 500 most differentially 
expressed genes of the single cell LRC and non-LRC were depicted. LRC gene expression 
was more homogenous between the single cells of the LRC group compared to the gene 
expressions of the non-LRC group indicating a higher heterogeneity in the non-LRC 
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population (see Figure 25A). Furthermore, GEP of LRC and non-LRC in the single cell 
analysis were clearly distinct in the PCA. The non-LRC population was located on the left 
side of the PCA, whereas the LRC population was across, demonstrating a different GEP 
pattern between both cell populations (see Figure 25B). Some LRC were more similar in their 
GEP to the non-LRC population than to the LRC population and vice versa. This observation 
in the PCA confirmed the high plasticity, which was already described in the LRC mouse 
model (see 1.3.1). 
Bulk RNA-seq was performed for ALL-199 LRC and non-LRC. The advantage of bulk RNA-
seq was the higher sequencing depth allowing the detection of genes expressed at low levels 
(Bacher & Kendziorski. 2016). However, no statements about the homogeneity or 
heterogeneity of a population were obtained. The heatmap and the PCA in Figure 26 
demonstrated the differences in the GEP of ALL-199 LRC and non-LRC.  
 
          
Figure 26: GEP of ALL-199 LRC and non-LRC are distinct as determined by bulk RNA-seq. 
(A) Hierarchical clustering across the 500 most differentially expressed genes (padj < 0.01) in 4 biological 
replicates was performed and depicted as heatmap. Values were plotted relative to the average of non-LRC. (B) 
PCA of the 500 most variable genes in all 8 bulk samples is shown. Each dot indicates a bulk sample. 
 
The LRC and non-LRC from both samples were distinct in the GEP.  It was possible to detect 
gene expression differences in these two phenotypically different samples despite the high 
plasticity in this model.  
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All LRC and non-LRC sequencing data including ALL-199 and ALL-265 were summarized 
in one common GEP for further analysis and characterization of LRC (see 3.5.1). A combined 
LRC signature was defined. This LRC signature contained all significantly upregulated genes 
compared to non-LRC (around 250 genes with fold change > 1 and padj < 0.05; see Figure 39 
and Table 12 in the appendix). 
 
4.3.1.2 KEGG terms belonging to cell surface interactions are upregulated in LRC 
Characterization of LRC based on their GEP was performed using gene set enrichment 
analysis (GESA). GSEA is a statistical bioinformatic tool to identify enrichment of specific 
gene sets in a GEP. Over-represented gene sets result in a positive normalized enrichment 
score (NES) and vice versa. The more genes from a gene set are regulated in the same 
direction, the more significant and higher the NES is (Subramanian et al. 2005).  
For the first round of enrichment analysis, the KEGG (Kyoto Encyclopedia of Genes and 
Genomes) pathway terms were used as gene sets for GSEA. The KEGG database offers a 
collection of different pathways and terms (Kanehisa et al. 2012).  
A GSEA on the common LRC GEP (including ALL-199 and ALL-265) was performed with 
all available KEGG terms. The highly significant terms are summarized in Figure 27. All 
significantly downregulated KEGG terms are associated with cell cycle and proliferation 
confirming the dormant state of LRC. 
In the upregulated KEGG terms cell adhesions molecules and cytokine-cytokine receptor 
interactions were highly enriched in GEP of LRC as compared to non-LRC. However, no 
specific pathway with a high enrichment score was significantly upregulated in LRC.  
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Figure 27: KEGG pathways for proliferation are downregulated and cell-cell interactions are upregulated 
in LRC. 
Significantly enriched KEGG pathways (padj < 0.01) are listed as determined by gene set enrichment analysis 
(GSEA). All RNA-seq data from ALL-199 and ALL-265 are combined for one common LRC GEP. Bars show 
the normalized enrichment score (NES). 
 
The metabolism in dormant cells differ highly from proliferating cells, for example in 
expression levels of genes, which are involved in the cell cycle (Whitfield et al. 2006).  
Therefore, the major difference of the GEP of LRC compared to non-LRC was associated 
with the dormant state of LRC. 
 
4.3.1.3 Patient signatures with challenging features are enriched in LRC  
To obtain a better idea about the challenging role of LRC, I next investigated the association 
of the LRC gene expression profile with patients’ signatures. Therefore, GSEA was 
performed with published patients’ gene signatures. All gene signatures contained only highly 
significantly upregulated genes. 
First, a gene signature of ALL with high risk for relapse was correlated with the LRC GEP 
(see Figure 28A). In this signature gene expression profiles from 207 uniformly treated 
children with ALL were obtained before therapy start, and 15 genes were identified as high 
risk genes for relapse by consideration of patients’ outcome (Kang et al. 2010). 11 out of the 
15 genes were also detected in the RNA-seq data of LRC. These 11 genes were significantly 
upregulated in LRC indicated by the high enrichment of this gene signature with the LRC 
GEP. Unfortunately, the role of these enriched genes cannot be classified to one specific 
cellular function. 
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Next, a gene set from dormant CD34
+
 CML populations was compared with the GEP of LRC. 
This gene signature was obtained by profiling dormant CD34
+
 CML patient populations 
against dividing CD34
+
 CML cells (Graham et al. 2007), and was also enriched more in LRC 
than non-LRC. This result confirmed the quiescent phenotype of LRC (see Figure 28B). 
Furthermore, a leukemia stem cell (LSC) signature, created by the comparison of LSC and 
hematopoietic stem cells (HSC), was enriched in upregulated genes of LRC (see Figure 28C) 
(Saito et al. 2010). The detection of LSC in patients is associated with worse prognosis, 
leading to the hypothesis that also the presence of LRC might be a bad prognosis factor. 
 
 
Figure 28: LRC GEP shows a high correlation with published critical patients’ signatures. 
Gene set enrichment analysis (GSEA) for published signatures on high risk ALL cells (Kang et al. 2010), 
dormant CD34
+
 CML (Graham et al. 2007) and leukemia stem cells (Saito et al. 2010) were performed. All 
RNA-seq data from ALL-199 and ALL-265 are combined for one common LRC GEP. Adapted from (Ebinger, 
Özdemir et al. 2016). 
 
Taken together, all critical patients’ signatures for ALL high risk, dormancy and malignant 
stemness, are significantly enriched in the GEP of LRC compared to non-LRC. These results 
indicate that LRC resemble a high-risk population in ALL. The LRC mouse model can be 
used as a novel platform to develop new treatment strategies for eliminating challenging cells 
in the ALL therapy.  
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4.3.2 Gene expression profiles of PDX MRD cells 
Next, GEP of chemotherapy-resistant PDX MRD cells and untreated control cells for the 
samples ALL-199 and ALL-265 was determined by RNA-seq in order to understand the 
challenging feature of chemotherapy resistance on transcriptome level (see 4.3.1).  
PDX MRD cells were generated by polychemotherapy as described 4.1.1 and the cells were 
isolated from the bone marrow by making use of the transgenes (truncated NGFR for MACS 
enrichment and mCherry for FACS enrichment). From the bone marrow of a chemotherapy 
treated mouse around 40,000 PDX MRD cells (0.1% of PDX cells in the bone marrow) were 
isolated and sorted either directly into lysis buffer for bulk RNA-seq or into patient medium 
for single cell RNA-seq (see Figure 29).  
 
 
Figure 29: Scheme for generating PDX MRD and control cells for RNA-seq analysis. 
1x10
6
 freshly isolated or thawed transgenic PDX cells were injected into each mouse. PDX cells were positive 
for the following transgenes: mCherry, truncated NGFR and firefly luciferase. Leukemia engraftment and 
therapy effects were followed by in vivo imaging. After reaching high tumor load chemotherapy was initiated. 
VCR (0.25 mg/kg; i.v.) and Cyclo (100 mg/kg; i.p.) were injected weekly as combination therapy. The untreated 
control group received PBS. At MRD level of about 0.1% blasts in the bone marrow after 2-3 weeks of 
treatment, mice were sacrificed and the isolated PDX cells from the bone marrow were sorted either in 10 µl 
patient medium with 1,000 cells for single cell RNA-seq or in 80 µl TCL-buffer with 2,000 cells for bulk RNA-
seq. Adapted from (Ebinger, Özdemir et al. 2016). 
 
 
 
4.3.2.1 GEP of PDX MRD cells are distinguished from the controls  
Single cell RNA-seq was performed with the ALL-199 PDX MRD cells. GEP of 90 MRD 
and 31 control single cells were obtained. To compare the GEP of both populations, a 
heatmap with hierarchical clustering and a PCA were performed as described before in 
4.3.1.1. 
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Figure 30: GEP of PDX MRD and untreated control cells from ALL-199 are clearly distinct in single cell 
RNA-seq. 
For each PDX MRD and control sample, PDX cells of one mouse were sorted for single cell RNA-seq. (A) 
Hierarchical clustering and gene expression heatmap across the 500 most differentially expressed genes (padj < 
0.01) in 90 PDX MRD and 31 control single cells were performed. Values were plotted relative to the average of 
untreated control cells. (B) PCA of the 500 most variable genes in all 121 single cells is shown. Each dot 
indicates a single cell. Adapted from (Ebinger, Özdemir et al. 2016). 
 
The heatmap of the 500 most differentially expressed genes indicated that the PDX MRD 
cells differed from the untreated control cells and displayed a more homogenous population 
compared to control cells. Furthermore, both populations were clearly distinguishable in the 
PCA, although an overlap between both PDX populations was observed (see Figure 30).  
Bulk RNA-seq data was obtained for both PDX MRD samples (ALL-199 and ALL-265). In 
order to characterize the PDX MRD cells independent of any specific PDX sample features, 
all bulk RNA-seq data of both PDX samples were combined to one common PDX MRD GEP 
for further analysis (see 3.5.1). The 250 most significantly differentially expressed genes were 
plotted as a heatmap. The overlap between both PDX samples was not high. The highest 
upregulated genes in one sample were not the same in the other sample. However, the 
direction of the regulation was always the same indicating a common gene expression 
between the different PDX MRD samples (see Figure 31A). 
Additionally, the PCA with the 500 most variable genes of all bulk RNA-seq data confirmed 
the diversity between the two PDX samples, ALL-199 and ALL-265. The first component 
(PC1) with 87% variance separated both PDX samples. The sample ALL-199 was localized 
on the left side of the PCA and on the right side ALL-265. Nevertheless, both PDX MRD 
populations differed from their controls with a variance of 4% in the second component (PC2) 
and thereby showed a small overlap within gene expressions for PDX MRD cells independent 
to the PDX sample (see Figure 31).   
                                                                                                                                           Results 
71 
 
 
 
Figure 31: ALL-199 and ALL-265 differ highly in their GEP, whereas the PDX MRD GEP are similar. 
(A) Combined PDX MRD hierarchical clustering and gene expression of ALL-199 and ALL-265 are depicted in 
a heatmap across the 250 most differentially expressed genes (padj < 0.01; PDX MRD/Ctrl of ALL-265:each 
n=4; PDX Ctrl of ALL-199: n=8; PDX MRD of ALL-199: n=14). Values are plotted relative to the average of 
the control. ALL-265 bulk samples are symbolized in grey lines and ALL-199 bulk samples resulted in black 
lines. (B) PCA of the 500 most variable genes was performed for all 30 bulk samples. Each symbol indicates a 
bulk sample. 
 
In summary, the GEP of both PDX MRD populations differed from the untreated controls. 
Although a substantial difference in gene expression was observed between the two PDX 
samples ALL-199 and ALL-265, the existing overlap between the two PDX MRD 
populations enabled determining a common PDX MRD GEP signature for both samples. 
 
4.3.2.2 KEGG terms belonging to metabolism are downregulated in PDX MRD cells 
Next, a KEGG pathway enrichment analysis was performed using the common PDX MRD 
GEP of both PDX samples (ALL-199 and ALL-265) in order to identify the changes in the 
transcriptome of the PDX MRD cells induced by chemotherapy. Besides, the final question 
was to understand the chemotherapy resistance in the PDX MRD cells by using this 
bioinformatic analysis. 
KEGG terms for metabolism and proliferation were the most significant downregulated terms 
in the MRD population. In contrast, the cytokine-cytokine receptor interaction and cell 
adhesion molecule terms were upregulated in GEP of PDX MRD cells compared to the 
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untreated controls. Furthermore, some pathways were also significantly enriched in the 
upregulated genes of PDX MRD cells, for example the JAK-STAT pathway and diverse 
chemokine signaling pathways (see Figure 32).  
 
 
Figure 32: KEGG pathways for proliferation are downregulated in the GEP of PDX MRD cells. 
Significantly enriched KEGG pathways (padj < 0.01) were listed as determined by GSEA. All RNA-seq data 
from ALL-199 and ALL-265 are combined for one common PDX MRD GEP. Bars show the normalized 
enrichment score (NES).  
 
The results from the PDX MRD KEGG pathway analysis let assume a dormant state of the 
PDX MRD cells due to the downregulation of cell cycle associated KEGG terms. 
Chemotherapy resistance in the PDX MRD cells might be based on this dormant phenotype. 
Furthermore, the high upregulation of KEGG terms for microenvironment interactions 
indicate the dependency of the PDX MRD cells to the bone marrow environment.  
 
4.3.2.3 PDX MRD cells exhibit a dormant GEP 
The KEGG pathway analysis indicated a low metabolic and low cell cycle activity in the PDX 
MRD cells compared to untreated control cells. To investigate this observation GSEA were 
performed with gene signatures of E2F and MYC targets from the Molecular Signatures 
Database (Liberzon et al. 2015). The two gene signatures contain genes, which are 
upregulated by the transcription factors E2F or MYC. The downregulation of the E2F and 
MYC target genes correlated with a dormant and low proliferating cell cycle state (Dimova & 
Dyson. 2005; Zeller et al. 2003). In contrast, genes with pretended controversial functions are 
also summarized to one KEGG term. Therefore, these two signatures confirm more 
specifically and precisely the low cell cycle activity in the PDX MRD cells than KEGG terms.  
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Figure 33: PDX MRD cells exhibit a dormant GEP. 
GSEA for E2F and MYC targets from Molecular Signatures Database (MSigDB) were performed (Liberzon et 
al. 2015). All bulk RNA-seq data from ALL-199 and ALL-265 were combined for one common PDX MRD 
GEP. Adapted from (Ebinger, Özdemir et al. 2016). 
 
Targets genes from E2F and MYC were highly significant downregulated in the GEP of PDX 
MRD cells in the GSEA (see Figure 33). This observation correlated the PDX MRD GEP 
with a dormant phenotype. In conclusion, the combination chemotherapy over several weeks 
selected for PDX cells with low cell cycle activity.  
 
4.3.3 Gene expression profiles of LRC and PDX MRD cells are similar 
PDX MRD GEP correlates with a dormant phenotype and LRC are selected by their dormant 
state. Therefore, possible similarities in GEP of these two populations were investigated. 
GSEA with the LRC signature (see Figure 39) was performed on the PDX MRD GEP, and all 
single cell RNA-seq data of LRC and PDX MRD cells were combined in one PCA in order to 
identify similarities and differences between the different PDX populations with challenging 
features.  
The LRC signature was significantly enriched in the GEP of PDX MRD cells. Significantly 
upregulated genes in LRC were also mostly upregulated in PDX MRD cells (see Figure 34A). 
Furthermore, GEP of LRC and PDX MRD single cells were clearly distinguishable from their 
either proliferating or untreated controls in the PCA. All 105 dormant and chemotherapy-
resistant single cells of LRC and PDX MRD cells were uniformly localized in the lower part 
of the PCA in contrast to the proliferating, untreated control PDX cells, which were localized 
in the upper part (see Figure 34B).  
 
                                                                                                                                           Results 
74 
 
 
Figure 34: High correlation between the GEP of LRC and PDX MRD cells. 
(A) GSEA with the LRC signature was performed on the combined PDX MRD GEP. (B) All single cell RNA-
seq data from ALL-265 LRC/non-LRC and ALL-199 MRD/control cells are plotted using all shared expressed 
genes. Each dot indicates a single cell. Adapted from (Ebinger, Özdemir et al. 2016). 
 
Taken together, LRC constitute a small subpopulation of dormant PDX cells during 
engraftment of the leukemia. In comparison, the PDX MRD cells are a population of 
chemotherapy treated cells. Modern next generation sequencing techniques including single 
cell RNA-seq enabled comparing both populations despite the fact that only very minor cell 
numbers were available for analysis. The data of GEP showed that the two populations 
associated either with dormancy or drug resistance show high similarities and share adverse 
and clinically challenging features. 
 
4.4 LRC and PDX MRD cells resemble primary patient MRD cells  
In the ALL PDX mouse model two distinct and clinically relevant populations were 
described. LRC were identified by dormancy during leukemia engraftment, whereas drug 
resistance in long-term chemotherapy characterized PDX MRD cells.  
As a last step, I aimed at estimating the relevance of these challenging PDX populations from 
the mouse model to patients’ disease. In patients MRD cells are the most challenging cells for 
the treatment of leukemia and correlate with a high risk for relapse and a poor prognosis (see 
1.1.2) (Conter et al. 2010; van Dongen et al. 2015). 
Five patient samples at diagnosis and corresponding MRD samples were provided and sorted 
for RNA-seq by Prof. Renate Panzer-Grümayer and colleagues (St. Anna Kinderspital, 
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Vienna; see 2.1). These samples were derived from children with newly diagnosed B-cell 
precursor ALL at time point of diagnosis and after the first block of chemotherapy and 
regeneration at day 33. Cells were sequenced by our cooperation partner Prof. Wolfgang 
Enard. GEP of primary MRD cells were compared with matched diagnosis samples (see 
Figure 35A). The sequencing quality from 3 out of 5 primary MRD samples was of sufficient 
quality for further analysis. All 220 significantly differentially expressed genes are plotted in 
the heatmap shown in Figure 35B. The gene expression of diagnosis and MRD samples 
differed. The GEP of primary MRD samples was associated with a dormant phenotype in 
GSEA compared to GEP of diagnosis samples (see Figure 40 in the appendix).  
 
Figure 35: GEP from diagnosis and MRD of primary ALL samples are distinct. 
(A) Bulk RNA-seq was performed from primary diagnosis (n=5) and primary MRD (n=3) samples. Primary 
MRD samples were obtained after 33 days of treatment onset. 2,000 cells were sorted into 80 µl TCL-buffer for 
bulk RNA-seq. (B) Hierarchical clustering and gene expression heatmap across all differentially expressed genes 
(padj < 0.05) is shown. Values were plotted relative to the average of diagnosis. Adapted from (Ebinger, 
Özdemir et al. 2016). 
 
After obtaining RNA-seq data from primary MRD samples the next step was to show the 
relevance of LRC and PDX MRD cells to patients’ disease. In the first approach the LRC 
signature (see Figure 39 in the appendix) was used for GSEA in order to compare GEP of 
primary MRD cells with the PDX cells. The LRC signature was significantly enriched in the 
primary MRD GEP (see Figure 36A). Furthermore, in the second approach all GEP from 
RNA-seq bulk samples, including LRC, PDX MRD cells and patient MRD cells, were plotted 
with all the controls in one PCA. All the bulk samples with the challenging features were 
localized within the same cluster. The first variance (PC1) shows the difference between GEP 
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of LRC, PDX MRD and primary MRD bulk samples on the left side of the PCA and the 
control bulk samples  on the right side (see Figure 36B). 
 
 
Figure 36: GEP of dormant and chemotherapy-resistant PDX cells show a high correlation with the GEP 
of primary MRD cells. 
(A) GSEA with the LRC signature was performed on the primary MRD GEP. (B) All bulk RNA-seq data from 
LRC, PDX MRD, primary MRD and their controls are plotted using all shared expressed genes. Each symbol 
indicates a bulk sample. Adapted from (Ebinger, Özdemir et al. 2016). 
 
GEP of LRC and PDX MRD cells correlated significantly with GEP of primary MRD 
samples. Thus, the two PDX populations with the challenging features of dormancy and 
chemotherapy resistance reflect patients’ disease at the stage of MRD on the transcriptome 
level. Both PDX NSG mouse models provide a novel platform for studying patients’ MRD in 
further functional studies.         
 
Taken together, in the present work I established several preclinical PDX mouse models of 
chemotherapy and treatment resistance and were able to show that dormant ALL cells during 
engraftment localize to the same endosteal bone marrow region as normal hematopoietic stem 
cells. In contrast, the PDX MRD cells are localized more to perivascular regions after 
surviving long-term chemotherapy. Gene expression profiles revealed that dormant and drug 
resistant PDX ALL cells in the bone marrow display substantial similarities to similar cells in 
patients. Thus, the PDX models can be used in the future to better characterize and finally 
efficiently treat treatment resistant tumor cells in patients with ALL. 
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5 Discussion 
Acute lymphoblastic leukemia (ALL) patients reach often remission upon initial treatment 
with cytostatic drugs (Inaba et al. 2013; Pui et al. 2008). Remaining leukemic cells in 
remission, which are defined as minimal residual disease (MRD) cells, indicate a high risk for 
relapse resulting in poor prognosis. Novel therapies targeting MRD cells are urgently needed 
for the improvement of patients’ treatment (Buckley et al. 2013).  
However, the biology of MRD cells is currently not very well understood. In clinics, MRD 
cells are detected in bone marrow aspirates but are not functionally characterized 
(Bruggemann et al. 2010). So far in one trial a dormant subpopulation of patients’ MRD cells 
was identified in bone marrow aspirates, but was not further analyzed (Lutz et al. 2013). 
 
In the present study, I established a novel patient-derived xenograft (PDX) mouse model that 
mimics patients’ MRD. This model enables us for the first time to perform functional studies 
on these cells and provides new insights into the characteristics of MRD cells. Furthermore, 
the recently established label retaining cell (LRC) mouse model for identification of dormant 
PDX ALL cells was also characterized and compared with the PDX MRD mouse model in 
order to understand the relation between dormancy and chemotherapy resistance in ALL. 
 
5.1 PDX MRD mouse model mimics patients’ MRD in ALL  
The feasibility to study the biology of patients’ MRD is limited by the minute numbers of 
remaining leukemic cells isolated from bone marrow aspirates. In addition, the identification 
of the MRD cells from healthy bone marrow is challenging and inefficient in FACS due to the 
high phenotypic MRD variability regarding cell surface markers (van Dongen et al. 2015). To 
overcome these limitations, the PDX MRD mouse model was established. The transgenes 
(mCherry, truncated NGFR, luciferase) introduced in the PDX cells, simplified the detection 
and isolation of remaining chemotherapy treated leukemic cells in the xenograft model.  
While PDX models in acute leukemia are mostly used for preclinical treatment trials and for 
studying the role of the bone marrow environment, the PDX MRD mouse model provides a 
tool for the characterization of a critical cell population in patients’ treatment (Gao et al. 
2015; Liem et al. 2004; Townsend et al. 2016). This established mouse model is the first 
mouse model mimicking the MRD in acute leukemia. Several groups established also an 
acute leukemia PDX model in which the leukemia was treated by chemotherapy. However, 
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the focus of these studies was set on simulation of standard chemotherapy. Treatment 
responses of the induction chemotherapy were analyzed rather than the functional 
characterization of remaining leukemic cells after treatment. Nevertheless, these studies 
demonstrate the relevance of the PDX model for the prediction of therapeutic agents in 
clinics. The same anti-leukemic effects of cytostatic drugs are observed in patient as well as in 
the xenograft mouse model (Liem et al. 2004; Samuels et al. 2014; Zuber et al. 2009). This 
close proximity in treatment effects between mouse and human was made use for the 
establishment of the PDX model mimicking MRD. 
Thus, the PDX MRD mouse model is based on the treatment with conventional cytostatic 
drugs in ALL therapies in order to reach the MRD level (of less than 0.1% blasts in the bone 
marrow) as close as possible to clinics. The combination therapy of Vincristine (VCR) and 
Cyclophosphamide (Cyclo) and treatment over prolonged periods of time reduce high tumor 
loads to MRD level in contrast to monotherapies (see Figure 9). The used drug concentrations 
in the PDX MRD model are based on optimized treatment protocols for ALL (see Table 8 in 
methods). The leukemia is decreased by more or less the same chemotherapeutic stress as in 
patients. Several studies showed that a specific cellular response to cytostatic drugs depends 
on the used drug concentrations (Meng et al. 2007; Morgan & Holguin. 2002). Consequently, 
the cellular response of the PDX MRD cells to chemotherapy might be the same like in 
patients due to the same provided chemotherapeutic stress. 
The initial induction therapy in patients is based on a polychemotherapy and takes usually 4-6 
weeks until remission and detection of the first remaining MRD cells. A combination therapy 
of more than two cytostatic drugs, as it is used in patients, is not feasible in mice due to high 
toxicity. A reason for this limitation is most likely the different metabolic activity in humans 
and mice as the higher metabolic activity in mice causes different pharmacokinetics of the 
used cytostatic drugs (Demetrius. 2005; Nair et al. 2016; Sharma & McNeill. 2009). 
Nevertheless, the combination therapy with VCR and Cyclo was administered for 2-3 weeks 
under clinical relevant drug concentrations. The established PDX MRD model is as close as 
possible to patients’ treatment and MRD. 
 
In order to demonstrate the clinical relevance of the PDX MRD and the LRC mouse model, 
gene expression profiles (GEP) of the PDX cells and primary MRD cells were analyzed. 
MRD cells are the most critical cell population of patients’ treatment. They are 
chemotherapy-resistant, dormant and highly self-regenerative (Buckley et al. 2013; Lutz et al. 
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2013). These features related also to LRC and PDX MRD cells, which were shown in the 
functional in vivo studies (see 4.1; Ebinger, Özdemir et al. 2016). 
So far no GEP of primary ALL MRD cells existed. In clinics the MRD cells are identified to 
monitor therapy efficiencies but have not been isolated for further studies (Bruggemann et al. 
2010). With the help of our cooperation partners (Prof. Renate Panzer-Grümayer and Prof. 
Wolfgang Enard), GEP of primary ALL MRD cells could be obtained for the first time. A 
comparative RNA-seq data analysis of LRC, PDX MRD cells and primary MRD cells 
demonstrates a significant correlation between all populations (see Figure 36). PDX cells with 
challenging features of dormancy and chemotherapy resistance display a similar gene 
expression profile as primary MRD cells. In conclusion, both minor cell populations in the 
two distinct PDX mouse models mimic features of patients’ MRD cells. Additionally, several 
studies report also a high correlation in GEP between PDX cells and primary malignant cells 
and underline the proximity of the PDX models to patients’ disease as for example in lung 
cancer biology or in acute leukemia (Daniel et al. 2009; Wong et al. 2014). These results 
confirm the relevance and ability of the PDX models for characterizing patients’ diseases in 
vivo. 
In conclusion, the established PDX MRD mouse model provides an unique tool to study the 
biology of MRD as close as possible to patients’ MRD.  
 
5.2 Detection of acquired chemotherapy resistance in the PDX model 
The initial treatment after diagnosis is often successful in ALL patients. The leukemia burden 
is drastically reduced and consequently patients reach the remission. However, remaining 
MRD cells often give relapses with poor outcome due to chemotherapy resistance (Foo & 
Michor. 2014; Inaba et al. 2013; Pui et al. 2008). The evolution of chemotherapy resistance is 
poorly understood and so far no model exists to study this critical aspect in ALL biology. In 
functional studies of the PDX MRD model first evidences for evolution of chemotherapy 
resistance in ALL was observed.  
The two used PDX samples, ALL-199 and ALL-265, exhibit different sensitivities to VCR 
during long-term treatment. Over three months a VCR resistant subpopulation in ALL-265 
remained stable despite weekly treatment. In contrast, PDX ALL-199 cells were immediately 
eradicated by the same therapy (see Figure 10). Genetic differences between the PDX samples 
are most probably the reason for the different VCR sensitivities.  
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The VCR resistance in ALL-265 is either based on a resistant subpopulation within the 
sample or an acquired resistance favored by genetic alterations. In the PDX models the 
conservation of heterogeneity was already known and proven. PDX samples can consist of 
different subpopulations, which are not lost during passaging in mice (Cassidy et al. 2015). 
Furthermore, the mechanism for VCR resistance is also described for PDX B-ALL cells. The 
mode of action of VCR is based on binding to tubulin resulting in microtubule destabilization 
followed with mitotic arrest and cell death (Owellen et al. 1972). Ong and colleagues 
demonstrated that VCR resistant PDX B-ALL cells exhibit an increased level of polymerized 
tubulin. Mechanisms regulating the microtubule stability are involved in VCR resistance (Ong 
et al. 2008). However, this experiment in the present work cannot provide insights into the 
question whether the long-term VCR therapy selected either for a subpopulation with a 
genotype favoring the acquisition of VCR resistance or for an existing resistant subpopulation 
in ALL-265. Nevertheless, the formation of a VCR resistant population for several months 
was observed in vivo. This model can be used for further studies in order to understand 
treatment failures based on chemotherapy resistance.  
 
In contrast, the established PDX MRD model suggests an acquired chemotherapy resistance. 
PDX MRD cells were generated by the combination therapy with VCR and Cyclo, and were 
re-passaged. In the next in vivo treatment round with the same therapy the PDX MRD cells 
were slightly more resistant than the control cells, which were treated to MRD level for the 
first time. At the end of the therapy 2.5-fold more PDX MRD cells were detectable in the 
bone marrow compared to the control cells (see Figure 12). Homing and engraftment of both 
groups were identical. This observation is also consistent with the reported high leukemia 
stem cell (LSC) frequency in ALL. The ability of self-renewal is conserved in all ALL cells 
independent of any subpopulations. Therefore no differences in homing and engraftment was 
expected in this experiment (Abdullah & Chow. 2013; le Viseur et al. 2008; Morisot et al. 
2010; Pal et al. 2016).  
Predetermination might be the (or one) reason for the significant increase of remaining cells 
in the PDX MRD group, and can be explained by epigenetic mechanisms. Bhatla and 
colleagues suggested also that chemotherapy resistance in B-ALL may be driven by 
epigenetic changes (Bhatla et al. 2012). After first round of treatment the PDX cells might 
obtain an epigenetic predetermination resulting in faster adaption to the next round of 
chemotherapeutic stress. Most probably such a predetermination in the leukemic cells is based 
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on acquiring faster a dormant state in order to get resistant towards chemotherapy as the GEP 
of PDX MRD cells suggests a dormant phenotype (see Figure 33). 
A selection for a resistant subpopulation during the first treatment round is unlikely. The PDX 
MRD cells were as sensitive to chemotherapy at the beginning of the second treatment round 
as the control cells; otherwise the PDX MRD cells would show a clear drug resistance in the 
next passage. In the PDX MRD model three weeks of combination therapy with two drugs 
was sufficient to exhibit the process of acquiring chemotherapy resistance. To the best of our 
knowledge this model provides the first tool to monitor and study the evolution of 
chemotherapy resistance in ALL in vivo. 
Our data indicate that chemotherapy resistance in ALL-265 is acquired over a long period of 
drug treatment rather than the existence of a drug resistant subpopulation. 
 
5.3 Bone marrow mediated dormancy is crucial for chemotherapy 
resistance 
The functional LRC and PDX MRD studies reveal the importance of the bone marrow 
microenvironment. In both in vivo models a high plasticity between the PDX cells is 
observed. The two critical populations of LRC and PDX MRD cells are able to re-engraft in 
mice with the same efficiency as untreated and dividing control cells. No isolated cell 
population is enriched for self-renewal or stemness in the next mouse passage compared to 
the control cells. Besides, dormant LRC or chemotherapy-resistant PDX MRD cells arise 
even within the control cell population in the next passage (see 4.1.3; Ebinger, Özdemir et al. 
2016). The observed high plasticity in the two PDX mouse models is consistent with the non-
hierarchical and random ALL stem cell model as described before in 5.2. No ALL stem cell 
population, enriched in self-renewal, has been identified so far (le Viseur et al. 2008; Morisot 
et al. 2010).  
Our two distinct mouse models for identification of LRC and PDX MRD cells show 
microenvironment mediated dormancy and chemotherapy resistance (Ebinger, Özdemir et al. 
2016). Consequently, the localization of LRC and PDX MRD cells within the bone marrow 
were analyzed to understand the role of the microenvironment for the critical acquired 
features of dormancy and chemotherapy resistance.  
 
In the LRC model the dormant subpopulation of PDX cells localizes close to the endosteum 
in both samples, ALL-199 and ALL-265. During homing and engraftment the PDX cells 
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interact with the endosteal region in order to settle within the niche. Most probably the 
interaction with the bone marrow environment stimulates these cells to become quiescent. 
Some unidentified factors such as cytokines and cell surface receptors within in the niche 
might contribute to the induction of dormancy. This hypothesis is supported by our findings 
that in GSEA (gene set enrichment analysis) terms for cell surface and cytokine cytokine 
interactions are highly upregulated in LRC indicating the necessity of LRC-microenvironment 
interactions for dormancy (see Figure 27 in the results). Several groups also described the role 
of the endosteum in diverse hematopoietic disorders for the induction of dormancy. 
Osteoblasts and osteoclasts, which are the characteristic cells of the endosteum, are 
responsible for harboring dormant malignant cells by expressing diverse cytokines. 
(Boyerinas et al. 2013; Chen et al. 2014; Lawson et al. 2015).  
 
In contrast to LRC, the chemotherapy resistance in vivo initially let to the identification of 
PDX MRD cells. However, the observed resistance in the PDX MRD model is based most 
probably on the dormant state of PDX MRD cells. GEP of these cells clearly indicate a non-
dividing phenotype. Gene sets including E2F- and MYC target genes are highly 
downregulated in PDX MRD cells, which associates these cells with dormancy (Dimova & 
Dyson. 2005; Liberzon et al. 2015; Zeller et al. 2003). This acceptance is also confirmed by 
GEP of the sorted primary MRD cells, which exhibit also a dormant phenotype. Therefore, an 
endosteal cell localization was assumed for the remaining leukemic cells after 
ploychemotherapy. Besides, drug resistance in the bone marrow is associated with 
localization close to the endosteum (Duan et al. 2014; Jin et al. 2008).  
However, the PDX MRD cells from both samples, ALL-199 and ALL-265, are randomly 
distributed in the perivascular regions of the bone marrow without accumulation in the 
endosteum like observed for LRC. There is a clear discrepancy between the localization of 
PDX MRD cells and LRC.  
Recently, Hawkins and colleagues were the first to describe the localization of chemotherapy 
treated T-ALL PDX cells. Using intravital microscopy and analyzing the entire calvarium 
bone marrow in real time, a stochastic mechanism for chemotherapy resistance in T-ALL was 
developed. The remaining PDX cells during and after treatment are randomly distributed in 
their model. No specific accumulation pattern in the bone marrow was identified confirming 
the PDX MRD localization results (Hawkins et al. 2016). Furthermore, the authors observed a 
nearly complete depletion of osteoblasts during high tumor load in mice. In patients’ bone 
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marrow aspirates with more than 75% blast infiltration the loss of osteoblasts was also 
confirmed by Hawkins and colleagues (Hawkins et al. 2016).  
This described dramatic change of the endosteal region can be translated to our PDX model 
and can explain why the dormant PDX MRD cell population is not localized to the endosteum 
but is rather randomly distributed in the bone marrow. At day 10 after cell injection the 
leukemia in both samples was less than 1% of the entire bone marrow population (Ebinger, 
Özdemir et al. 2016). The structure of endosteal region including the osteoblasts should not 
undergo a drastic change at this early time point. As one possible explanation, the endosteum 
might provide a niche for untreated ALL cells such as LRC, but osteoblast depletion changes 
the endosteum dramatically disabling a protective niche in the post-treatment situation of 
PDX MRD cells. 
 
A yet undefined niche for dormancy could influence the perivascular localization of the PDX 
MRD cells. In the last decades the endosteum was associated with localization of dormant 
HSC. Even osteoblasts were described as the key component of the niche supporting HSC 
maintenance (Guezguez et al. 2013; Haylock et al. 2007; Xie et al. 2009; Zhang et al. 2003). 
In contrast, Kiel and colleagues doubted the influence of osteoblasts on HSC (Kiel et al. 
2007). Furthermore, Ding and Morrison were able to show two distinct niches of HSC and 
early lymphoid progenitors (ELP) in the bone marrow. HSC localized in a perivascular niche 
and ELP in an endosteal niche (Ding & Morrison. 2013). Nevertheless, the endosteal niche 
harboring ELP has to provide factors supporting dormancy due to the reversible quiescent 
state of ELP (Pelayo et al. 2006). Besides, it has been shown recently, that dividing as well as 
non-dividing HSC reside in small areas of the perivascular niche indicating an additional 
niche for dormant cells within the bone marrow (Acar et al. 2015). These controversies 
indicate that next to the endosteum a second niche for dormancy might exist in perivascular 
regions in the bone marrow. 
New insights in the malignant bone marrow niche are always associated with the healthy 
hematopoiesis. Leukemic cells always interact with normal healthy bone marrow cells, before 
capturing niche elements of HSC and disrupting the healthy hematopoiesis (Boyd et al. 2014; 
Colmone et al. 2008). Therefore, my assumption is that the PDX MRD cells localize in 
dormant perivascular niches as recently described for HSC (Acar et al. 2015). However, the 
question remains open, why LRC predominantly use the endosteal niche for dormancy and no 
other niches during engraftment. 
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A possible explanation for the endosteal localization of LRC might be an observation during 
the engraftment at day 3 and day 10 after cell injection. The percentage of PDX cells localized 
to the endosteum is significantly higher at day 3 compared to day 10. The endosteum seems to 
contribute mainly to PDX ALL homing and engraftment. Ishikawa and colleagues reported 
similar observations for the acute myeloid leukemia (AML) in their PDX model (Ishikawa et 
al. 2007).  
During homing in the endosteum, some PDX cells may get dormant and reside as LRC in this 
niche during engraftment. However, the necessity of the endosteal region for engraftment 
differs between ALL-199 and ALL-265. ALL-265 is highly enriched in the endosteal region 
during the first two weeks after cell injection. In contrast, ALL-199 localize to a lower degree 
to the endosteum. Nevertheless, the LRC and PDX MRD cells of both samples show a similar 
localization pattern within the bone marrow indicating the importance and the unique 
functions of these two different niches for dormancy and chemotherapy resistance. 
 
Taken together, dormancy of LRC and PDX MRD cells is based on the interactions with the 
bone marrow environment. However, both PDX populations localize to different niches. 
During engraftment LRC reside in the endosteal niche, which is associated with dormancy. At 
high leukemia burden the endosteal niche undergoes a change due to the depletion of 
osteoblasts, and consequently the function of this niche to localize dormant cells might be 
destroyed (Hawkins et al. 2016). The PDX MRD cells, which survive combination 
chemotherapy for several weeks, predominantly localize in the perivascular regions of the 
bone marrow suggesting that some areas of the perivascular niche replace the dormant 
function of the endosteal niche.  
 
 
5.4 High correlation of GEP from two populations within distinct PDX 
models is based on dormancy 
In this study the method of RNA-seq was used for transcriptome analysis of LRC and PDX 
MRD cells in order to characterize and understand the challenging features of dormancy and 
chemotherapy resistance in ALL. The first step towards this aim was to obtain GEP of both 
critical PDX cell populations. A clear difference in the gene expressions from LRC/PDX 
MRD cells and their proliferating untreated controls was confirmed by principle component 
analysis (PCA) and let to the generation of each GEP. 
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Since almost two decades GEP are used as data sets to explore the relations and associations 
between different cells, diseases and therapies (Alizadeh et al. 2000; Khan et al. 2001; van 't 
Veer et al. 2002). Consequently, the GEP of LRC was classified by several gene set 
enrichment analysis (GSEA) with published gene signatures to confirm the challenging 
features of LRC observed in the functional studies. The applied gene signatures correlated 
highly with the LRC GEP, for example genes associated for dormant CML (chronic myeloid 
leukemia) cells or AML LSC (leukemia stem cell) were enriched in the GEP of LRC (Graham 
et al. 2007; Saito et al. 2010). The dormant state of LRC shows a similar regulation in the 
transcriptome like the dormant primary CML cells indicating a universal GEP for dormancy 
independent of diverse malignancies.  Besides, the GEP of LRC includes genes that are 
involved in stemness, like in the AML LSC. These bioinformatical results confirm the 
observed LRC features of dormancy and self-renewal in the functional studies (Ebinger, 
Özdemir et al. 2016).  
Due to the high capacity of self-renewal in ALL no gene signatures of sorted ALL 
subpopulation with challenging features are available (le Viseur et al. 2008). In AML the 
CD34
+
 CD38
-
 cell population is associated with stemness. Therefore, many gene signatures 
for AML LSC are published (Gal et al. 2006; Gentles et al. 2010; Hackl et al. 2015). 
However, Kang and colleagues generated a signature for ALL to predict the risk for relapse. 
This signature for relapse prediction was generated by comparing patients’ outcomes and 
gene expressions before therapy start (Kang et al. 2010). GSEA with this gene signature 
showed a high enrichment in the GEP of LRC. LRC seems to be a surrogate for relapse 
inducing cells. Unfortunately, the enriched genes in this signature cannot be assorted to one 
particular/specific pathway or cellular mechanism in order to understand the risk for relapse in 
detail. 
 
We were the first who identified and isolated dormant as well as chemotherapy-resistant cells 
from a single sample by using two distinct PDX models. PDX MRD cells are characterized by 
chemotherapy resistance after 2-3 weeks of treatment, and LRC are characterized by 
dormancy during leukemia engraftment. Therefore, it is more surprising that the GEP of both 
critical PDX populations are similar (see Figure 34). Most probably the similarity of the GEP 
is based on the dormant phenotype of both populations. GSEA of PDX MRD cells revealed 
also a dormant phenotype (see Figure 33).   
Dormancy seems to be a common and reversible feature in ALL cells like described for HSC 
(Wilson et al. 2008). Hence, novel therapies aiming to reduce the relapse risk and increase 
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patients’ outcome have to target ALL dormancy. Dormant ALL cells have to be turned into 
proliferating cells in order to sensitize them towards chemotherapy. Such treatment strategies 
are also suggested in different hematological disorders. However, the proof of concept for this 
novel treatment approaches is still missing (Boyerinas et al. 2013; Takeishi et al. 2013). 
Functional studies from LRC and PDX MRD cells showed a microenvironment mediated 
dormant phenotype in ALL (see 4.1.3; Ebinger, Özdemir et al. 2016). Nevertheless, the 
leukemic cells have to be targeted instead of the bone marrow microenvironment. The high 
controversy in the bone marrow niche and our limited knowledge about the interaction of 
bone marrow cells prevent to use the microenvironment as a therapy target (see 5.3) (Boyd et 
al. 2014; Calvi & Link. 2014; Hawkins et al. 2016). Furthermore, the obtained RNA-seq data 
of LRC and PDX MRD cells offer an unique platform to identify targets/candidates on the 
ALL cells.  
However, the question remains, whether it is possible to target both critical PDX populations 
by inhibiting one candidate. The bone marrow localization of LRC and PDX MRD cells are 
completely different and so the neighboring cells in the two distinct niches are most probably 
disparate. In contrast, the GEP of LRC and PDX MRD cells are very similar and an overlap 
of candidates exists for sure. Therefore, the chance might be high that the inhibition of 
LRC/PDX MRD cell interaction with the niche is possible by using one candidate. The 
assumption is that both niches of LRC and PDX MRD cells use the identical mechanism for 
keeping these cells dormant.  
 
5.5 Conclusion and outlook 
The present study developed a novel preclinical mouse model and enabled novel insights into 
the biology of dormant and treatment resistant ALL cells. The data obtained allow the 
conclusion that resolving resistant cells from their protective bone marrow niche supporting 
dormancy might sensitize them towards chemotherapy. 
The present work allows future studies to prove this concept and to test novel treatment 
options against MRD in a preclinical setting. The data approximate the global aim to develop 
novel therapies which eliminate resistant and dormant tumor cells in ALL, to prevent ALL 
relapse and to finally improve the prognosis of patients with ALL.  
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6 Appendix 
6.1 Supplemental figures 
 
Figure 37: Commonly used cytostatic drugs in patients’ ALL therapy show a different and dose-
dependent growth inhibition of ALL-265. (related to 4.1.1) 
After reaching high tumor load, different cytostatic drugs were applied once a week into mice. Each therapy 
group consists of two mice. * Eto 50 mg/kg therapy group had to be sacrificed due to high weight loss (> 10% 
after therapy start). 
 
 
 
Figure 38: The mCherry antibody staining correlates with the CFSE signal of PDX cells. (related to 4.2.1) 
CFSE
+
 mCherry
+
 PDX cells were injected into mice. Femurs were fixed with zinc formalin for femur 
preparation. Fixation destroyed the mCherry signal, but not the CFSE signal. Femur sections of day 3 after cell 
injection were stained with an anti-mCherry antibody. The CFSE signal at day 3 was strong enough to be 
detected by confocal microscopy and served as positive control. 
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Figure 39: LRC signature from combined RNA-seq data of ALL-199 and ALL-265. (related to 4.3.1) 
LRC signature genes (padj < 0.05 and log2 fold-change >1) were derived from combined bulk and single-cell 
RNA-seq analysis from 6 animals carrying either ALL-265 or ALL-199 and are shown ranked by fold-change 
and colored by significance. In Table 12 (in the appendix) the genes of the LRC signature are listed. Adapted 
from (Ebinger, Özdemir et al. 2016). 
 
 
 
 
Figure 40: Primary ALL MRD samples are dormant compared to their diagnosis samples. (related to 4.4) 
GSEA for E2F and MYC targets from Molecular Signatures Database (MSigDB) (Liberzon et al. 2015) were 
performed. All bulk RNA-seq data from patients’ diagnosis and MRD samples were combined for a primary 
MRD GEP. 
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6.2 Supplemental tables 
                              Table 11: Expected absolute and relative LRC numbers in the  
    entire bone marrow/femur based on FACS data (related to 4.2.3) 
 ALL-199 
dpi 
abs. LRC 
number  
% of LRC 
to PDX 
% of LRC 
in one femur 
day 10 35,000 2% 0.015 
day 14 7,000 0.06% 0.003 
    
 ALL-265 
dpi 
abs. LRC 
number in bm 
% of LRC 
to PDX 
% of LRC 
in one femur 
day 10 3,000 1.1% 0.001 
day 14 2,100 0.02% 0.0007 
                             dpi = days post injection; abs. = absolute; assumption of around  
                             11x10
6
 hematopoietic cells in one femur  
  
 
 
Table 12: Common LRC signature (log2 fc > 1 
and padj < 0.05) of ALL-199 and ALL-265 
(related to Figure 39) Adapted from (Ebinger,  
Özdemir et al. 2016). 
Rank Gene Name log2 fc padj 
1 H1F0 3.49 1.17E-45 
2 HSD11B1 3.17 3.12E-22 
3 NEIL1 2.83 1.72E-23 
4 AC116366.5 2.65 2.00E-16 
5 MTUS2 2.58 2.45E-17 
6 HIST1H2AC 2.57 1.01E-33 
7 FLT3 2.30 2.95E-21 
8 C10orf10 2.29 1.19E-19 
9 CYTL1 2.22 4.16E-60 
10 MS4A6A 2.21 4.84E-11 
11 CD97 2.21 1.34E-13 
12 TMEM173 2.10 2.51E-19 
13 NFE2 2.10 1.94E-13 
14 NT5E 2.04 8.22E-13 
15 CD86 2.04 1.14E-09 
16 TP53INP1 2.01 6.96E-14 
17 SETBP1 1.99 9.12E-09 
18 LGALS1 1.99 4.99E-10 
19 GSN 1.97 1.25E-22 
20 HSH2D 1.96 5.20E-16 
21 RAB37 1.95 2.38E-16 
22 ABHD4 1.94 1.14E-11 
23 HIST1H4H 1.91 1.26E-10 
24 EMR2 1.91 4.26E-08 
25 ENSG00000229164 1.89 2.47E-12 
26 EMP1 1.89 6.49E-12 
27 ITGA6 1.87 4.50E-18 
28 LINC00114 1.86 3.59E-09 
29 HRK 1.85 1.51E-07 
30 CST7 1.82 1.26E-07 
31 MYO1F 1.81 6.28E-10 
32 PDGFA 1.81 2.11E-07 
33 NOTCH2 1.81 8.35E-13 
34 SERPINE1 1.80 1.83E-07 
35 FAIM3 1.80 4.01E-20 
36 NRXN3 1.80 3.73E-07 
37 TOX2 1.79 4.63E-07 
38 NCF1C 1.78 1.29E-12 
39 HIST2H2BE 1.77 5.41E-14 
40 DUSP26 1.77 6.33E-07 
41 C15orf52 1.76 9.58E-08 
42 CD70 1.75 4.89E-09 
43 METTL7A 1.74 7.41E-11 
44 LINC00707 1.74 3.52E-08 
45 MYRIP 1.72 6.08E-10 
46 SAMHD1 1.72 3.95E-14 
47 NCF1B 1.72 4.66E-13 
48 RP11-473M20.9 1.71 7.25E-08 
49 TNFSF4 1.71 2.01E-07 
50 RIN2 1.68 9.90E-09 
51 TPST1 1.68 2.88E-08 
52 SERPING1 1.66 8.31E-08 
53 PIK3IP1 1.65 2.72E-16 
54 NCF1 1.65 3.95E-14 
55 ADAM19 1.63 1.38E-07 
56 DHRS7 1.61 4.66E-13 
57 P4HA2 1.59 3.06E-08 
58 DNASE2 1.58 1.17E-05 
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59 ADAM8 1.57 4.48E-06 
60 CD1C 1.56 9.35E-11 
61 MYLIP 1.55 3.81E-11 
62 SDK2 1.55 6.26E-06 
63 LINC01021 1.54 2.33E-06 
64 IL24 1.54 1.71E-05 
65 PLEKHG1 1.54 6.34E-06 
66 HIP1 1.52 3.71E-05 
67 Y_RNA 1.50 9.13E-06 
68 PTGER4 1.49 3.64E-05 
69 ZMAT3 1.49 2.19E-09 
70 KLF4 1.49 6.68E-06 
71 ARL4C 1.49 3.62E-05 
72 FERMT2 1.48 7.36E-05 
73 GBP2 1.46 8.50E-05 
74 LPAR6 1.45 1.14E-20 
75 IL1B 1.45 3.21E-18 
76 ZNF555 1.44 2.84E-06 
77 TERF2 1.43 4.69E-23 
78 FOLR2 1.43 2.20E-06 
79 FCGRT 1.40 1.12E-13 
80 S100A10 1.40 1.70E-04 
81 PAN3 1.40 2.36E-17 
82 LRMP 1.40 1.34E-20 
83 NOTCH2NL 1.39 1.60E-04 
84 CDKN2D 1.38 1.05E-15 
85 CTSH 1.37 6.18E-14 
86 DUSP1 1.37 5.47E-10 
87 OSBPL10 1.37 8.69E-05 
88 ANTXR1 1.36 1.14E-04 
89 FOSB 1.35 8.89E-06 
90 SELM 1.35 2.26E-04 
91 OSER1-AS1 1.34 4.08E-04 
92 LGR6 1.34 1.42E-04 
93 C10orf25 1.33 1.20E-05 
94 RHOC 1.33 3.39E-05 
95 PLAUR 1.33 4.85E-07 
96 FBXO25 1.33 2.08E-04 
97 B3GNT5 1.32 4.35E-04 
98 ENSG00000117289 1.32 1.36E-12 
99 CLMN 1.32 4.80E-06 
100 FAM3C 1.31 4.11E-07 
101 CA5B 1.30 5.54E-08 
102 LYST 1.30 1.83E-07 
103 RASSF4 1.29 1.71E-04 
104 RGS16 1.28 1.34E-04 
105 SH3BP2 1.28 3.32E-08 
106 TNFRSF10D 1.28 5.70E-05 
107 PPP1R15A 1.28 8.19E-09 
108 ITGAM 1.27 9.23E-04 
109 MACROD2 1.27 7.80E-05 
110 ITGB2 1.27 8.88E-08 
111 GADD45B 1.26 1.84E-07 
112 HGSNAT 1.26 7.85E-04 
113 CLEC4E 1.26 3.31E-04 
114 IPCEF1 1.26 2.47E-12 
115 PLXNB1 1.25 1.30E-03 
116 CRMP1 1.25 1.24E-05 
117 LGALS3BP 1.25 4.55E-13 
118 SULF2 1.25 1.18E-03 
119 N4BP2L1 1.25 8.36E-07 
120 C16orf54 1.24 6.83E-10 
121 NEAT1 1.24 7.66E-11 
122 CEP112 1.24 4.56E-04 
123 TIMP1 1.23 1.29E-09 
124 SMAD3 1.23 3.45E-06 
125 OAS1 1.23 9.07E-07 
126 RASAL2 1.22 1.57E-04 
127 FOS 1.22 8.28E-04 
128 THEMIS2 1.22 7.43E-09 
129 AC005154.6 1.22 4.05E-05 
130 CXCR4 1.22 6.43E-10 
131 CSRNP2 1.21 1.95E-04 
132 CD44 1.21 6.85E-09 
133 TNFAIP2 1.21 2.22E-03 
134 GPR183 1.21 1.18E-03 
135 SPRY1 1.20 1.37E-03 
136 TSC22D3 1.20 7.17E-10 
137 RP11-154D3.1 1.20 2.33E-03 
138 PLXND1 1.19 1.71E-03 
139 LSP1 1.19 4.49E-05 
140 ID2 1.19 1.92E-03 
141 YPEL2 1.19 3.78E-04 
142 LINC01013 1.18 2.55E-09 
143 ENSG00000182217 1.18 8.67E-08 
144 ENSG00000183941 1.17 7.75E-08 
145 CTD-3252C9.4 1.17 3.26E-03 
146 MS4A7 1.17 1.39E-04 
147 BHLHE40 1.17 1.21E-03 
148 TLR1 1.17 5.47E-05 
149 HSPB1 1.16 5.70E-10 
150 ANKRD28 1.16 5.80E-07 
151 RAP1GAP2 1.16 2.00E-03 
152 HLA-E 1.15 3.21E-18 
153 GIMAP4 1.15 1.66E-05 
154 DDIT4L 1.15 6.09E-10 
155 BTG1 1.15 3.21E-07 
156 CD37 1.15 2.07E-05 
157 HCST 1.15 1.58E-05 
158 HVCN1 1.15 1.88E-08 
159 KIAA1407 1.15 4.51E-03 
160 RP11-325F22.2 1.14 3.69E-04 
161 RYBP 1.14 5.63E-07 
162 ENSG00000163386 1.14 7.60E-07 
163 EMP3 1.14 3.39E-05 
164 ANTXR2 1.14 2.49E-06 
165 SMAGP 1.13 3.71E-06 
166 HIST1H1C 1.13 1.58E-09 
167 KLF6 1.13 1.40E-06 
168 LITAF 1.13 1.42E-06 
169 ARID5B 1.12 2.04E-07 
170 LINC-PINT 1.12 2.25E-04 
171 CBR3 1.12 7.85E-04 
172 SFXN3 1.12 5.04E-03 
173 RP11-474J18.1 1.11 5.38E-03 
174 NR4A1 1.11 6.30E-03 
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175 HIST1H2BK 1.11 7.97E-08 
176 RAB29 1.10 1.58E-03 
177 NEGR1 1.10 2.22E-04 
178 GCSAM 1.10 4.30E-05 
179 TGFBR2 1.10 6.20E-05 
180 ICAM3 1.10 1.70E-04 
181 PSAT1 1.10 2.53E-08 
182 ARMCX4 1.10 1.92E-03 
183 IGFBP7 1.10 6.35E-03 
184 AMICA1 1.09 6.80E-03 
185 F11R 1.09 2.73E-04 
186 IFITM3 1.09 8.49E-08 
187 RP11-556E13.1 1.09 6.34E-03 
188 PSAT1P3 1.09 1.24E-03 
189 PCNXL2 1.09 7.63E-03 
190 RYK 1.08 8.32E-03 
191 EFNA1 1.08 3.59E-05 
192 KLF3 1.08 3.55E-05 
193 NEDD9 1.08 1.08E-03 
194 HSBP1L1 1.07 2.93E-03 
195 CDC42EP3 1.07 9.17E-03 
196 CMTM2 1.06 1.47E-06 
197 CECR1 1.06 1.65E-03 
198 CASC15 1.06 1.04E-02 
199 SYNE2 1.06 9.08E-04 
200 TMCO4 1.06 3.53E-04 
201 RHOB 1.06 7.70E-03 
202 RGL1 1.05 2.79E-08 
203 FOSL2 1.05 1.58E-04 
204 ENSG00000183558 1.05 8.21E-05 
205 CD9 1.04 1.10E-09 
206 ZNF252P 1.04 1.59E-06 
207 SPNS3 1.04 1.00E-02 
208 HSPB1P2 1.04 2.51E-03 
209 ARHGEF3 1.04 6.03E-04 
210 C9orf89 1.04 1.24E-04 
211 DPEP1 1.03 7.85E-03 
212 RP11-301G19.1 1.03 1.52E-07 
213 GDPD1 1.03 9.85E-03 
214 PCDH9 1.03 1.15E-02 
215 HIST2H2AA4 1.03 1.23E-04 
216 MX1 1.03 3.31E-04 
217 CAP2 1.03 4.68E-03 
218 KIAA2026 1.03 4.82E-05 
219 TEX41 1.02 1.47E-02 
220 CAPG 1.02 1.45E-10 
221 PLP2 1.02 2.53E-05 
222 ZNF441 1.02 1.03E-02 
223 ATF3 1.02 6.04E-03 
224 ZBTB20 1.02 9.32E-03 
225 IRAK2 1.02 1.34E-02 
226 SPTA1 1.02 1.61E-04 
227 RP4-725G10.4 1.02 1.27E-06 
228 CAPN2 1.02 3.59E-04 
229 S100A6 1.02 3.45E-09 
230 WWC3 1.02 8.93E-03 
231 ZCCHC7 1.01 9.36E-13 
232 HLA-G 1.01 4.50E-09 
233 RNASET2 1.00 5.45E-10 
234 HLA-W 1.00 6.03E-04 
235 ZBTB4 1.00 1.54E-02 
236 FAM3C2 1.00 1.14E-02 
237 HSPB1P1 1.00 4.69E-04 
238 UBXN11 1.00 3.56E-04 
239 TP53INP2 1.00 1.94E-02 
240 XAF1 1.00 1.08E-04 
241 ZFP36 1.00 1.09E-02 
242 KCTD7 1.00 5.88E-03 
243 RP11-705C15.2 1.00 3.71E-05 
244 GLDC 1.00 1.02E-02 
245 KLHL24 1.00 6.51E-05 
246 GCHFR 1.00 1.20E-03 
247 C20orf194 1.00 3.31E-04 
248 IGLL1 1.00 6.68E-12 
249 PLXNC1 1.00 1.12E-02 
250 IL3RA 1.00 2.07E-02 
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6.3 R-packages and version numbers 
R version 3.3.1 (2016-06-21) 
Platform: x86_64-w64-mingw32/x64 (64-bit) 
Running under: Windows >= 8 x64 (build 9200) 
 
locale: 
[1] LC_COLLATE=German_Germany.1252  LC_CTYPE=German_Germany.1252    
[3] LC_MONETARY=German_Germany.1252 LC_NUMERIC=C                    
[5] LC_TIME=German_Germany.1252     
 
attached base packages: 
 [1] grid      parallel  stats4    stats     graphics  grDevices 
 [7] utils     datasets  methods   base      
 
other attached packages: 
 [1] BiocInstaller_1.22.3       org.Hs.eg.db_3.3.0         
 [3] AnnotationDbi_1.34.4       ggplot2_2.1.0              
 [5] ComplexHeatmap_1.10.2      DESeq2_1.14.0              
 [7] SummarizedExperiment_1.2.3 Biobase_2.32.0             
 [9] GenomicRanges_1.24.3       GenomeInfoDb_1.8.7         
[11] IRanges_2.6.1              S4Vectors_0.10.3           
[13] BiocGenerics_0.18.0        
 
loaded via a namespace (and not attached): 
 [1] mclust_5.2           Rcpp_0.12.7          locfit_1.5-9.1       
 [4] mvtnorm_1.0-5        lattice_0.20-33      circlize_0.3.9       
 [7] class_7.3-14         plyr_1.8.4           chron_2.3-47         
[10] acepack_1.4.1        RSQLite_1.0.0        GlobalOptions_0.0.10 
[13] zlibbioc_1.18.0      diptest_0.75-7       data.table_1.9.6     
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8 Abbreviations 
°C   degree Celsius 
µm   micrometre (10
-6
 m) 
ALL   acute lymphoblastic leukemia 
APC   allophycocyanin 
BCP   B-cell precursor 
BM   bone marrow 
BSA   bovine serum albumin 
CAR   CXCL12-abundant reticular   
CD   cluster of differentiation  
cDNA   complementary deoxyribonucleic acid 
CFSE   carboxyfluorescein succinimidyl ester 
cm   centrimetre (10
-2
 m) 
CML   chronic myelogenous leukemia 
CSC   cancer stem cell 
ctrl   control  
Cyclo   Cyclophosphamide 
d   days  
DAPI   4′,6-Diamidin-2-phenylindol 
dd H20   double-distilled water  
DE   differential expression 
Dexa   Dexamethasone 
DMSO  Dimethylsulfoxid 
DNA   deoxyribonucleic acid 
EDTA   Ethylenediaminetetraacetic acid 
ELP   early lymphoid progenitor 
Eto   Etoposide 
F    female 
FACS   fluorescence-activated cell scanning 
fc   fold change   
FCS   fetal calf serum 
FSC   forward scatter 
g    relative centrifugal force 
g    gram 
GEO   gene expression omnibus 
GEP   gene expression profile 
GSEA   gene set enrichment analysis 
h   hour   
HPC   hematopoietic progenitor cell 
HSC   hematopoietic stem cell 
Hz   Hertz (60/min) 
i.p.   intraperitoneal 
i.v.   intravenous 
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IHC   immunohistochemistry 
KEGG   Kyoto Encyclopedia of Genes and Genomes 
kg   kilo gram (10
3
 g)  
lg   logarithm 
LIC   leukemia initiating cell 
LRC   label retaining cell 
LSC   leukemia stem cell  
m    meter 
M    molecular mass 
MACS   Magnetic Activated Cell Sorting 
mg   milligram (10
-3 
gram)  
min   minute 
ml   millilitre (10
-3 
litre)  
mM   millimolar (10
-3 
molecular mass) 
MRD   minimal residual disease 
mRNA  messenger ribonucleic acid 
MSC   mesenchymal stem cell 
MSigDB  Molecular Signatures Database 
n    absolute number 
na   not available  
NES   normalized enrichment score 
NGFR   human low affinity nerve growth factor receptor 
nm    nanometer (10
-9
 m) 
NSG   NOD scid gamma 
padj   p-value adjusted 
PBE   PBS including EDTA 
PBS    phosphate buffered saline 
PC   principle component 
PCA   principle component analysis 
PCR   polymerase chain reaction 
PDX   patient-derived xenograft 
PE   Phycoerythrin 
pen/strep  penicillin streptomycin 
RNA-seq  ribonucleic acid sequencing 
RT   room temperature   
s    second 
sr    steradian 
SSC   side scatter 
untr.   untreated 
UV   ultraviolett     
v/v   volume/volume 
VCR   Vincristine 
VSD   variance stabilizing data 
w/v   weigth/volume 
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